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CHAPTER 1 – SIGNIFICANCE AND AIMS 
 
 
1.1  Significance 
 
Cell migration is an intricate process that is important during immune responses and 
cancer metastasis.  Immune cells must be able to migrate throughout the body in order to 
properly mount effective immune responses.  Similarly, a successful metastatic cancer cell must 
also be able to migrate from the primary tumor to a secondary site.  Cell migration is carried out 
via a process called chemotaxis, in which cells sense gradients of chemoattractants, through their 
chemotactic receptors.  Activation of chemotactic receptors leads to downstream signaling 
processes required for integrin-mediated migration.  Integrins are adhesion proteins that allow 
the cell to adhere to surfaces, propel itself along these surfaces and de-adhere so that the cycle 
can be repeated.  Both immune cells and cancer cells use specific chemotactic receptors to signal 
to integrins in order to mediate migration to precise locations that express specific gradients of 
chemokines.  
Under normal conditions immune cells constantly migrate throughout the body scanning 
lymphoid organs and other tissues looking for foreign invaders, such as bacteria or viruses.  
Immune cells use chemotactic receptors to migrate into specific areas of the body such as the 
bone marrow, lymph nodes, lungs and brain.  T lymphocytes are major players in the immune 
response as they are important for activating B lymphocytes, secreting cytokines that further 
amplify the immune response, retaining memory that allow for a quicker immune response and, 
in certain cases being cytotoxic.   The chemokine CCL21 is highly expressed in high endothelial 
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venules (HEVs), and through unknown signaling mechanisms, directs naïve T lymphocytes that 
express C-C Chemokine Receptor 7 (CCR7) into lymph nodes from the blood through HEVs.  
Inside lymph nodes, the chemokines CCL19 and CCL21 direct naïve T lymphocytes that express 
CCR7 into regions of the lymph node where they can interact with other cells such as B 
lymphocytes and dendritic cells.  In the lymph node naïve T lymphocytes scan dendritic cells 
that present an antigen, broken down bacterial or viral peptides, which the naïve T lymphocyte 
can recognize.  Dendritic cells also express the chemokine CCL19 which attract naïve T 
lymphocytes to their vicinity.  If a naïve T lymphocyte fails to recognize antigen presented by a 
dendritic cell, a mechanism is in place that will allow the naïve T lymphocyte to exit the lymph 
node and to migrate to other lymph nodes where the cells can continue to look for antigen it 
recognizes.  However, if a T lymphocyte recognizes antigen presented by the dendritic cell, the 
naïve T lymphocyte becomes activated, differentiates, exits the lymph nodes and migrates into 
the periphery to participate in the inflammatory response.  It is during an extended period of time 
of T lymphocyte/dendritic cell interactions that exit mechanisms are up-regulated, yet it is 
unclear what specific signal(s) is/are required to turn on this machinery and promote egress from 
the lymph node.  During over-exaggerated allergic reactions and autoimmune disorders, T 
lymphocytes recruited to areas of inflammation can cause severe damage and even death.  
Therefore, it is important to be able to regulate the migration of naïve T lymphocytes before or 
while they are in lymph nodes, before they have the opportunity to exit lymph nodes and move 
into areas of inflammation as activated effector T lymphocytes and create further destruction of 
tissues.   
Many types of metastatic cancers, such as breast cancer, exploit the same molecular 
mechanisms used by lymphocytes to become motile and migrate into specific organs.  CCR7 is 
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up-regulated in metastatic breast cancers and has been correlated with metastasis to lymph nodes.  
Because CCR7’s role in lymphocyte migration is to direct cells into the lymph nodes, there have 
only been strong correlations but no observations in vivo that demonstrate that CCR7 mediates 
this same process in breast cancer cells.  Furthermore, at present it is unclear what CCR7 
mediated mechanisms might control lymph node metastasis.  Taken together, CCR7 represents a 
primary target that can potentially be used to regulate autoimmunity and breast cancer 
metastasis.  The results of my dissertation project have increased our knowledge of the molecular 
mechanisms that contribute to CCR7 mediated migration through its ligands CCL19 and CCL21 
in naïve T lymphocytes and development of a mouse model to study CCR7 mediated metastasis 
of breast cancer to the lymph nodes outlined in the three following chapters:   
 
Chapter 3)  CCR7/CCL21 Migration is Mediated by PLCγ1 and ERK1/2 in Primary T  
Lymphocytes. 
 
Chapter 4)   CCR7/CCL19 Mediates T Lymphocyte Expression of EDG-1. 
 
Chapter 5)  Expression of a Chemokine Receptor, CCR7, Mediates Metastasis of Breast Cancer 








CHAPTER 2 – BACKGROUND 
 
2.1  Cellular Migration 
 
   Cell migration is a multifaceted process that requires activation followed by de-
activation of adhesive contacts, polarization of the appropriate signaling molecules and a 
chemokine/growth factor gradient of which to migrate towards [1].  As cells migrate along the 
extracellular matrix they use adhesive contacts called integrins.  Integrins are unique receptors 
that can be activated by “inside out” signaling which occurs through activation of another cell 
surface receptor, such as a chemokine receptor, or “outside in” signaling which occurs via a 
ligand binding to the integrin itself [2].  Integrins are heterodimeric proteins that are made up of 
an α and β subunit.  During integrin activation these subunits are typically in an extended 
conformation, while during de-activation the subunits return to a bent/folded confirmation [3].  
When a cell receives a signal to move, integrins are rapidly polarized to the leading edge of the 
cell where they bind the extracellular matrix [4, 5].  Force is then generated through interactions 
with the actin cytoskeleton and the cell is then propelled over the extracellular matrix [6].  The 
integrins then release from the extracellular matrix and are recycled back into the cell to repeat 
the cycle again [7].   
 As described in Chapter 1, naïve T lymphocytes must be able to enter into and migrate 
within lymph nodes in order to encounter antigen presenting dendritic cells and they rely greatly 
on β1 integrins to accomplish this task [8].  β1 integrins bind to collagen I and IV, Vascular Cell 
Adhesion Molecule-1 (VCAM-1), laminin and fibronectin.  Both laminin and fibronectin are 
expressed in high endothelial venules, the point of entry for lymphocytes migrating into lymph 
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nodes [9, 10].  Chemokine activation results in β1 integrin polarization at the leading edge of 
migrating cells and increased activation of β1 integrins [4, 8].  In human naïve T lymphocytes 
activation of CCR7 by its ligand CCL21 results in firm adhesion, tethering and rolling on 
VCAM-1, a β1 integrin ligand. [11, 12].  However, the molecular mechanisms of how CCR7 
signals to β1 integrins to induce migration to lymph nodes remain unclear.    
 
2.2  Organization and Function of the Lymph Nodes 
 
 Lymph nodes are small bean shaped structures linked together by lymphatic vessels that 
are found throughout the entire body.  Regardless of size, lymph nodes are one of the most 
important sites for cellular interaction and activation of immune responses.  The lymph node is 
divided into two individual regions including the cortex and the medulla [13] (Figure 1).  The 
cortex can be further divided into two regions including the paracortex which is also known as 
the T cell area and the node cortex that includes the B cell area [14].  The paracortex (T cell area) 
is the location where T lymphocytes and dendritic cells interact and where lymphocytes enter 
into lymph nodes through high endothelial venules, a rich source of CCL21 [15].  The paracortex 
is populated with fibroblastic recticular cells, which are a source of CCL19 and CCL21 [16].  As 
lymph nodes are sites of continuous cell chemotaxis they therefore express many types of 
extracellular matrix molecules that assist in cell migration to different compartments including 
collagen, laminin, vitronectin and fibronectin [17, 18].  
 Lymph nodes are central sites of antigen presentation, cell to cell interactions and 




Figure 1. Organization of the lymph node. Lymph nodes are important sites of cellular
interaction and activation of immune responses. The lymph node is divided into two regions,
the cortex and the medulla. The cortex is further divided into the paracortex and node cortex.
The paracortex includes the T lymphocyte area where high endothelial venules (HEV) are
located. High endothelial venules are the entry point for T lymphocytes and express CCL21.
In the paracortex T lymphocytes (T) expressing CCR7 interact with dendritic cells (DC) that
express CCL19. The paracortex is also populated with fibroblastic recticular cells (FRC)
expressing CCL19 and CCL21. The cortex is the B lymphocyte area and under inflammatory



































maturation and migrate to regional lymph nodes, where they will display antigen for recognition 
by naïve T lymphocytes.  Naïve T lymphocytes migrate toward lymph nodes, entering into the 
lymph nodes through high endothelial venules where they first encounter CCL21.  Upon entering 
the lymph nodes naïve T lymphocytes immediately begin to scan dendritic cells that express 
CCL19 [19], which facilitates interactions between the two cell types.  In the absence of antigen 
naïve T lymphocytes and dendritic cells can make upwards of 5,000 contacts per hour, which is 
amplified during an immune response [20, 21].  In the presence of antigen, naïve T lymphocytes 
during early stages of interaction with dendritic cells, will make transient contacts that last for 
minutes, with little activation detected among the T lymphocytes [22].  Following these brief 
interactions, naïve T lymphocyte will form stable interactions with dendritic cells that can last up 
to 36-48 hours [22].  During this stable interaction the T lymphocyte becomes activated, 
proliferates and eventually detaches from the dendritic cell [23].  Lastly, the activated T 
lymphocytes exit the lymph nodes and return to the circulation to carry out their effector 
functions in the periphery.   
 
2.3  C-C Chemokine Receptor 7 (CCR7) and its Ligands CCL19 and CCL21   
 
 CCR7 is expressed by naïve T lymphocytes, mature dendritic cells (DC), natural killer 
cells (NK), central memory T cells and T regulatory cells (Tregs) [24].  CCR7 binds two 
chemokine ligands, CCL19 and CCL21.  CCL19 is expressed in the thymus, spleen, stromal cells 
of the lymph nodes, and dendritic cells [16, 25, 26].  CCL21 is expressed in the appendix, spleen, 
high endothelial venules and stromal cells of the lymph nodes [16, 27, 28].  To date the major 
role of CCR7 in immunity is to direct T lymphocyte migration into secondary lymphoid organs 
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such as the lymph nodes.  The importance of this function lies in the positioning of cells within 
the lymph node such that activation of effector cell subsets like T and B lymphocytes occurs.  If 
T lymphocytes fail to come into contact with antigen presenting dendritic cells either because the 
dendritic cells can’t migrate to the lymph node or T lymphocytes can’t find the dendritic cells in 
the lymph node, then T lymphocytes simply do not become activated.  In addition, if T 
lymphocytes are unable to find and activate B lymphocytes, then the immune response is 
diminished.  In support of this function, mice lacking CCR7 have severely reduced numbers of 
CD4+ T cells in lymph nodes while increased numbers of these cells are found in the blood and 
bone marrow [29].  In addition, there is structural rearrangement of lymph nodes, such as B cell 
follicles in the paracortex, which are normally located in the cortex and lymph nodes are also 
devoid of T cell areas normally located in the paracortex [29].  CCR7 knockout mice also have 
impaired T cell and B cell activation and diminished lymphocyte responses during immune 
challenge [29].    
In mice CCL21 is expressed in two forms that differ at nucleotide position 65, resulting 
in one that encodes a serine and the other a leucine [30].  The leucine form is expressed in non-
lymphoid tissues while the serine form is expressed in lymphoid tissues and resembles the 
expression pattern of human CCL21 [30].  Paucity of lymph node T cells (plt) is a spontaneous 
mutant in mice that results in the deletion of both CCL21 (serine form expressed in lymphoid 
tissue) and CCL19 [16, 30].  Similar to the CCR7 knock out mouse, plt mice display a loss of T 
cells and DCs in the lymph nodes, spleen and Peyer’s patches and as expected plt are more 
susceptible to viral infections [31].  Recent studies have demonstrated a role for CCL19 and 
CCL21 in the development of lymph nodes, Peyer’s patches and spleen [32, 33].  However, 
studies from the plt mouse make it difficult to delineate specific roles for each ligand.   
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The development of a CCL19 knock out mouse and CCL19 (8-83) and CCL21 (mSLC4) 
antagonists have provided more insight into the role for these ligands.  A study carried out in a 
CCL19 knock out mouse revealed that CCL19 was not essential for development of lymphoid 
tissue and lack of CCL19 did not affect the ability of naïve T cells to migrate into secondary 
lymphoid organs, suggesting that CCL21 may be more important for these functions [34].  In 
support of these studies, it has been shown that ectopic expression of CCL21 alone is sufficient 
for development of lymphoid tissue in pancreatic islets [35].  Antagonists developed against 
CCL19 (8-83) and CCL21 (mSLC4) also suggest more important functions.  Similar to the 
CCL19 knock out mouse, the CCL19 antagonist 8-83 does not affect the ability of lymphocytes 
to enter into lymph nodes, however lymphocytes accumulate in peripheral and mesenteric lymph 
nodes during an immune response, suggesting that CCL19 might play a role in lymphocyte 
egress from lymphoid tissues [36].  In support of these studies, use of the CCL21 antagonist 
(mSLC4) determined that cells failed to migrate efficiently into secondary lymphoid organs [37].  
Although a clear predominate role has emerged for CCL21 in mediating migration into lymph 
nodes and a possible role for CCL19 mediating egress has been suggested, the precise molecular 
mechanisms of these process are not understood.  
 
2.4  G-Protein Coupled Receptors  
 
G-protein coupled receptors (GPCRs) are involved in many everyday human sensations.  
For example, they are the detection molecules for light, odor and taste as well as hormones, 
neurotransmitters and chemokines.  GPCRs play a role in many important physiological 
processes including neurological, cardiovascular, endocrine and immunity [38].  Therefore, it is 
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not surprising GPCRs are a major target for drug discovery and that 60% of all drugs available 
today target GPCRs[39].   
GPCRs are large transmembrane receptors that span the membrane seven times and 
couple to G-proteins to transmit signals into the cell.  When a G-protein coupled receptor binds 
to a ligand the receptor undergoes a conformational change that results in coupling to a G protein 
[40].  G proteins are heterotrimeric molecules made up of α, β and γ subunits.  Receptor 
activation results in an exchange of guanosine diphosphate (GDP) for guanosine triphosphate 
(GTP) on the Gα subunit of the G protein.  The Gα-GTP bound subunit then dissociates from the 
Gβγ subunit [41].  Once dissociation occurs each subunit then can initiate downstream signaling 
events.  The Gα subunit family is composed of Gαs, Gαi, Gαq and Gα12/13 and is responsible 
for regulating activity of adenylyl cyclase, calcium channels, tyrosine kinases, mitogen protein 
activated kinase (MAPK), and phospholipase C (PLC) [42].  Gβγ subunits can also activate a 
variety of signaling molecules including G-protein receptor kinases (GRKs), 
phosphatidylinositol 3-kinase (PI3K), MAPK and PLC [42].  Activation of the Gα and Gβγ 
pathways leads to cellular events such as proliferation, differentiation and migration. 
 
2.5  Entrance into Lymph Nodes:  Signaling Through the CCR7 Receptor in T Lymphocytes  
 
 As previously mentioned G-protein coupled receptor activation of downstream signaling 
events requires coupling to a G-protein.  Pertussis toxin specifically targets the Gαi family of G-
proteins and adenosine diphosphate (ADP) ribosylates the Gαi subunit resulting in the inability 
of the G-protein to interact or couple with the receptor [43].  Studies using pertussis toxin have 
demonstrated that CCR7 couples to the Gαi G-protein and is required for migration to CCL21 
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and CCL19 [44, 45].  Additionally, CCR7 mutants that lack the C-terminal tail of the receptor 
also are unable to activate the Gαi subunit resulting in a loss of extracellular signal-related kinase 
1and 2 (ERK1/2) activation and migration [46].   
Following GPCR activation and release of Gα/Gβγ subunits, CCR7 becomes 
phosphorylated at its C terminus, which allows for binding of arrestins (commonly referred to as 
β-arrestin 1 or β-arrestin 2).  Arrestins are important for receptor internalization, migration and 
act as adaptor proteins that mediate signaling through multiple proteins such as MAPKs [47] 
(Figure 2).  Interestingly, β-arrestin 1 or β-arrestin2 are not required for CCR7 mediated 
migration in response to CCL21 activation [48].  In contrast, both β-arrestin 1 and β-arrestin 2 
are required for migration to CCL19 [48].  Additionally, depletion of β-arrestin 2 lead to a loss of 
ERK1/2 phosphorylation in HEK293 cells stimulated with CCL19 [49].   
Mitogen Activated Protein Kinase (MAPK) signaling is required for many cellular 
functions such as differentiation, survival and migration.  G-protein coupled receptors are well 
known for their ability to activate MAPK signaling cascades [50-52].  Stimulation of CCR7 with 
either CCL19 or CCL21 results in phosphorylation of the MAPK, ERK1/2 in HEK293 cell lines 
[49].  In primary T and B lymphocytes ERK1/2 is rapidly and transiently phosphorylated in 
response to CCR7 stimulation by CCL21 [53, 54].  Rapid and transient phosphorylation of 
ERK1/2 in aortic smooth muscle cells is necessary for migration [55], suggesting that transient 
phosphorylation of ERK1/2 might also be required to induce migration of naïve T lymphocytes.  
However, to date it remains unclear if transient phosphorylation of ERK1/2 is required for CCR7 
















Figure 2. Requirement for arrestins during CCR7 signaling. Both β-arrestin 1 and β-
arrestin 2 are required for migration to CCL19, but not CCL21. Depletion of β-arrestin 2















In addition to MAPKs, GPCRs also are well known for their ability to activate the 
phospholipase C family of proteins which include PLCA, PLCβ, PLCD and PLCγ.  
Phospholipase C proteins can regulate cell motility by binding to the actin cytoskeleton as well  
as interacting with adhesion proteins such as integrins to control migration.  In lymphocytes 
PLCγ1 plays an important role in cytoskeletal rearrangement, cell spreading and migration [56-
58].  Activation of PLCγ1 results in hydrolysis of phosphatidyl inositol (4,5) bisphosphate (PIP2) 
to inositol (1,4,5) triphosphate (IP3) and diaglycerol (DAG) [59].  In T lymphocytes IP3 
regulates calcium mobilization and together with DAG can regulate activation of Ras, through 
the Ras activator RasGRP [60].  Through the activation of Ras, PLCγ1 activation indirectly 
contributes to activation of MAPK pathways, which are important for controlling cell migration 
[61].  Another way that PLCγ1 controls migration is that it directly binds to and activates β1 
integrins [62].  β1 integrins are important for T lymphocyte transendothelial migration into 
lymphoid organs.   CCR7 phosphorylation of PLCγ1 is required for migration of head and neck 
cancer cells to CCL19 [63].  However, it is not clear if PLCγ1 activation is important for 
migration to CCL19 or CCL21 in T lymphocytes. 
 
2.6  Sphingosine-1-Phosphate Receptor 1 and Lymph Node Egress 
 
 As naïve T lymphocytes migrate throughout the body traveling into lymphoid organs, 
they must be able to navigate their way back out and either migrate onto other secondary 
lymphoid organs or into the periphery to carry out effector functions.  The Sphingosine-1- 
phosphate receptor 1 (S1P1), is expressed on T lymphocytes and is required for lymphocyte 
egress from the thymus, spleen, Peyer’s patches and lymph nodes [64, 65].  The ligand for the 
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S1P1, sphingosine 1 phosphate (S1P) is expressed at high concentrations in blood (100-300nM) 
and acts as a gradient to attract cells from lymphoid organs [66].   Interestingly, twenty-four 
hours following T lymphocyte entry into lymph nodes, T lymphocytes lose the ability to migrate 
to S1P, correspondingly mRNA for the receptor is decreased 1-10% [64, 65].  Approximately 
three days following T cell receptor activation, mRNA for S1P1 is increased and cells once again 
regain the ability to migrate to S1P and rapidly reappear in circulation [65].  During this three 
day period, T lymphocytes remain in lymph nodes where they interact with dendritic cells that 
express CCL19, become activated and proliferate (Figure 3).  Kruppel Like Factor 2 (KLF2), a 
transcription factor, regulates S1P1 expression.  Similar to S1P1, KLF2 mRNA mirrors the cyclic 
expression levels of S1P1 during an immune response [67].  However, the precise signal that 
leads to increased KLF2 transcription resulting in increased S1P1 transcription to allow for 
lymphocyte egress from lymph nodes remains unclear. 
 One possible upstream candidate for KLF2 activation is the MAPK, extracellular signal-
related kinase 5 (ERK5).  ERK5 is expressed in T lymphocytes and is phosphorylated in 
response to T lymphocyte activation (anti-CD3 and anti-CD28) or IL-7 stimulation [68].  ERK5 
directly regulates KLF2 expression in T lymphocytes [68].  Depletion of ERK5 leads to down-
regulation of CD62L [68].  CD62L is also known as L-selectin and is an adhesive molecule 
expressed on the surface of naïve T lymphocytes and plays a role in homing of these cells into 
secondary lymphoid organs.  Consequently, only cells that express high levels of CD62L can 
efficiently migrate to S1P [65].  Because depletion of ERK5 leads to down-regulation of CD62L 
on the surface of T lymphocytes, this suggests that migration to S1P could also be diminished.  
These results suggest a possible role for ERK5 in regulating S1P1 expression.  However, anti-
























Figure 3. S1P1 regulates T lymphocyte lymph node egress. Naïve T lymphocytes (T)
enter into lymph nodes where they begin scanning dendritic cells (DC) that present antigen.
Twenty fours hours after entering into the lymph nodes, T lymphocytes down-regulate S1P1
expression. Following brief interactions with the dendritic cells, naïve T lymphocytes will
form stable interactions with the dendritic cells that can last 36-48 hours. During this period
of time the T lymphocyte will become activated and proliferate. Approximately, 72 hours
following T lymphocyte activation S1P1 mRNA is increased and cells regain the ablility to
migrate to S1P, which is at a higher concentration in blood. This results in T lymphocytes
exiting the lymph node. We proposed that CCL19, which is expressed by dendritic cells
provides the signal necessary for increased expression of S1P1. We propose that CCL19





activation is only induced over a short period of time and S1P1 is regulated over the course of 
days.  In contrast, during the ~48 hour time period that T lymphocytes form conjugates with 
dendritic cells in the lymph nodes, the T lymphocytes are consistently stimulated with CCL19  
expressed by dendritic cells.  Interestingly, in CCL19 knockout mice retention of both CD4+ and 
CD8+ cells occurs in lymph nodes during normal homeostasis [34].  In a similar study using a 
CCL19 antagonist (8-83), cells were also retained in lymph nodes during an allogenic immune 
response [36].  Furthermore, in CCR7 deficient mice S1P1 levels were also found to be decreased 
[69] suggesting that CCR7 expression may be important for S1P1 expression.  These studies 
together suggest a possible role for CCR7/CCL19 in lymphocyte egress from lymph nodes 
(Figure 3). 
  
2.7  Potential Role for CCR7 Signaling in Lymph Metastasis During Breast Cancer Progression 
 
 According to the American Cancer Society, breast cancer is the second leading cause of 
cancer deaths among women in the United States with an estimated 207,090 new cases in women 
and 1,970 new cases in men occurring in 2010.  It is estimated that approximately 40,000 women 
will lose their lives to breast cancer in the United States this year alone.  While the 5 year 
survival rate has drastically improved to 90%, the rate for survival if the breast cancer has 
metastasized to distant lymph nodes and organs is a staggering 23% [70].   
Metastasis is a complex process whereby a cell detaches from a primary tumor and 
migrates to a second site.  In recent years, it has been recognized that cancers tend to not 
randomly metastasize to distant sites, but instead favor certain metastatic sites over others.  For 
example, breast cancers typically metastasize to the bone, lung, liver, brain and lymph nodes.  
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These reoccurring sites of metastasis have been explained due to the expression of chemokine 
receptors on the surface of breast cancer cells that respond to gradients of chemokines located in 
target organs.  In particular, CXCR4 and CCR7 are expressed on human breast cancer cells and 
are considered diagnostic biomarkers that predict lymph node metastasis [71-73]. 
 Lymph nodes have not always been thought of as sites of metastasis.  Instead lymph 
nodes have been considered as sentinel sites where metastases simply filter through on their way 
to other organs.  It is not known if tumor cells become trapped in the lymph nodes or continue to 
metastasize to distant organs.  In any case, staging of breast cancer relies heavily on lymph node 
involvement, with greater involvement correlating to a worse disease outcome [74].  In most 
breast cancer cases, axillary lymph nodes are removed without a comprehensive understanding if 
removal is clinically better/worse for patient survival, as lymph nodes are important site for 
immunological responses [74].  Recent studies found strong correlations that human breast 
cancers expressing CCR7 specifically metastasize to lymph nodes, which highly express CCR7 
ligands, CCL19 and CCL21 [73, 75].  However, a contrasting study determined that CCR7 
expression did not correlate with lymph node metastasis in breast cancer [76].  At present, it is 
unclear if and by what mechanisms CCR7 controls lymph node metastasis in breast cancer. 
  
2.8  CCR7 Signaling in Breast Cancer Cells 
 
As lymphocytes are experts at migrating and entering into tissues, cancer cells take 
advantage of the same machinery used by lymphocytes to also metastasize and invade tissue.  
Therefore, we can learn an abundant amount of information about the molecular mechanisms 
involved in these processes in cancer cells through our knowledge of lymphocyte behavior.  
18 
 
CCR7 is up-regulated in many types of metastatic cancers including gastric, pancreatic, thyroid, 
endometrial, lung and breast and is implicated in lymph node metastasis [77-81].  Similar to T 
lymphocytes, CCR7 activates the MAPK, ERK1/2, in cancer cells to induce migration and 
inhibition of either CCR7 or ERK1/2 results in reduction of migration and invasion [82].  In T 
lymphocytes PLCγ1 plays an important role in cell migration and β1 integrin activation [56, 57, 
62].  In head and neck cancer cells, CCR7 mediated migration requires activation of PLCγ1 [83].  
PLCγ1 has also been found to be indispensable for activation of β1 integrins in cancer cells [84].  
Additionally, in thyroid carcinoma cells, stimulation of CCR7 by CCL21 increased β1 integrin 
expression on the cells surface [79].   
Similar to T lymphocytes, β1 integrins have been identified as important mediators or 
breast cancer migration.  Compared to the primary tumor, metastatic breast cancer cells display 
increased expression of β1 integrins on their cells surface [85].  Blocking β1 integrins reverts the 
malignant phenotype of these breast cancer cells to a normal epithelial phenotype, characterized 
by well organized actin, organized adherens junctions, deposition of a basement membrane and 
growth arrest [85].  Additionally, use of AIIB2 a β1 integrin functioning antibody, in 
combination with radiation therapy significantly enhanced the effects of the radiation therapy 
and reduced the tumor size in human cells and in vivo [86].  A better understanding of how 
CCR7 regulates β1 integrin up-regulation or activation can advance our understanding of how 
breast cancer cells become metastatic and invade surrounding tissue.  Finally, a better 
understanding of the role of CCR7 in mediating breast cancer metastasis to lymph nodes is 





CHAPTER 3- CCR7/CCL21 MIGRATION ON FIBRONECTIN IS MEDIATED BY 
PLCγ1 AND ERK1/2 IN PRIMARY T LYMPHOCYTES 
 
 
3.1  Abstract 
 
C-C Chemokine receptor 7 (CCR7) binds to its cognate ligand, CCL21, to mediate the 
migration of circulating naive T lymphocytes to the lymph nodes. T lymphocytes can bind to 
fibronectin, a constituent of lymph nodes, via their 1 integrins, which is a primary mechanism 
of T lymphocyte migration; however, the signaling pathways involved are unclear. We report 
that Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) is required for T cell migration on 
fibronectin in response to CCL21 with a rapid (within 2 minutes) and transient phosphorylation 
of ERK1/2. Conversely, prevention of ERK1/2 phosphorylation by inhibition of its kinase, MEK, 
prevented T lymphocyte migration. Previous studies have suggested that Phospholipase C 
gamma 1 (PLC1) can mediate phosphorylation of ERK 1/2, which is required for 1 integrin 
activation. Paradoxically, we found that inhibition of PLC1 phosphorylation by the general PLC 
inhibitor, U73122, was associated with an enhanced phosphorylation of ERK1/2 and reduced 
migration of T lymphocytes on fibronectin. To further characterize the relationship between 
ERK1/2 and PLC1, we reduced PLC1 levels by 85% using shRNA and observed a sustained 
phosphorylation of ERK1/2 and a significant reduction in CCR7 mediated migration of T 
lymphocytes on fibronectin. In addition, we found that inhibition of ERK 1/2 phosphorylation by 
U0126 resulted in a decreased phosphorylation of PLC1 suggesting a feedback loop between 
ERK 1/2 and PLC1. Overall, these results suggest that the CCR7 signaling pathway leading to T 
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lymphocyte migration on fibronectin is a 1 integrin dependent pathway involving transient 
ERK1/2 phosphorylation, which is modulated by PLC1. 
 
3.2  Introduction 
 
     G-protein coupled receptors (GPCRs) are responsive to many types of stimuli such as 
hormones, neurotransmitters and chemoattractants.   Ligand activation of a GPCR causes a 
conformational change in the receptor that leads to an exchange of GDP for GTP in the Gα 
subunit and dissociation of Gα from the Gβγ subunits.  The subunits then initiate downstream 
signaling events to regulate activation of adenylyl cyclase or phospholipase C (PLC) [42].  C-C 
Chemokine Receptor 7 (CCR7), a G-protein coupled receptor, is expressed on naive T 
lymphocytes and is required for migration into and within lymph nodes.  CCR7 binds to two 
ligands CCL19 and CCL21.  CCL21 is expressed in high endothelial venules, the entry route into 
lymph nodes [28].  However, it is currently unknown how T lymphocytes signal through CCR7 
to mediate migration via β1 integrins in response to CCL21.   
     Integrins, which are key mediators of lymphocyte adhesion and migration, are heterodimeric 
adhesion proteins, consisting of an α and the β subunit, for which they are named.  β1 integrins 
which are expressed by T lymphocytes and bind to VCAM, collagen and fibronectin [87].  
Fibronectin is a major component of the lymph node and is highly expressed in the cortex in the 
presence of fibroblastic recticular cells, which express CCL21[17, 88].  This network provides an 
environment that allows CCR7 expressing T lymphocytes to migrate throughout the lymph node.   
     Phospholipase C (PLC) is a downstream target of Gβγ signaling and is important for T cell 
migration [89].  PLCγ binds to and activates β1 integrins [62].  Furthermore, PLCγ1 is required 
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for adhesion to fibronectin and important for β1 integrin mediated cell migration [63, 84].  
PLCγ1 was recently shown to be phosphorylated by CCR7 in head and neck cancer cells and was 
necessary for migration of squamous cell carcinoma of head and neck cells [83].     
     GPCRs can activate the downstream effector mitogen activated protein kinases (MAPK) to 
regulate chemotactic migration [53, 90].  In HEK293, CCR7 transient transfectants, stimulated 
with CCL19 rapidly activated extracellular related kinase 1/2 (ERK1/2), while CCL21 had a 
minimal effect on ERK1/2 phosphorylation [46].  In primary B lymphocytes that express 
endogenous CCR7, CCL21 mediated activation of ERK1/2 [53].  These contrasting studies 
illustrate the importance of determining the role of ERK1/2 in the migration of primary T 
lymphocytes to CCL21.  
     Therefore, we examined the molecular mechanisms that are required for β1 integrin activation 
and β1-mediated migration.  In primary T lymphocytes we have found that CCL21 promotes 
activation of PLCγ1 and transient activation of ERK1/2, which are required for β1 integrin 
activation in response to CCL21.  Loss of activation of either PLCγ1 or ERK1/2 prevented 
migration via β1 integrins to CCL21.  These results indicate that CCL21 activation of CCR7 
promotes activation of β1 integrins leading to migration following phosphorylation of PLCγ1 
and ERK1/2.  
 
3.3  Results 
 
3.3.1  Primary Lymphocytes Differentially Migrate to CCL21 on Fibronectin 
  Naïve T lymphocytes which express CCR7, enter into lymph nodes in response to CCL21 
expressed in high endothelial venules.  To define the molecular mechanisms that control CCL21 
22 
 
mediated T lymphocyte migration we used chemotaxis assays.  Naïve T lymphocytes were 
induced to migrate over a physiological range of CCL21 concentrations (0-400nM).  We found 
that naïve T lymphocytes migrated to CCL21 at 2μM concentration on polycarbonate 
membranes (Figure 4A).  To understand how T lymphocytes migrate via β1 integrins we pre-
incubated the polycarbonate membranes with the β1 integrin ligand, fibronectin.  Lymphocytes 
were induced to migrate over a wide physiological concentration to 0-400nM CCL21, with the 
greatest migration occurring at 40nM (Figure 4B). These results implicate β1 integrins in T 
lymphocyte migration to CCL21. 
 
3.3.2  ERK1/2 is required for Migration to CCL21 
 GPCRs can activate extracellular signal related kinase (ERK1/2) in order to mediate 
migration of human primary macrophages and human osteosarcoma cells [90, 91].  To examine 
the role of ERK1/2 in the migration of naïve T lymphocytes to CCL21 via their β1 integrins, we 
examined migration to CCL21 in the presence of the MEK inhibitor UO126.  Under these 
conditions naïve T lymphocytes failed to migrate on fibronectin compared with controls treated 
with vehicle (DMSO) (Figure 5A).  To confirm that UO126 blocked MEK activation of ERK1/2, 
we used western blots.  As expected, UO126 blocked ERK1/2 phosphorylation in cells treated 
with CCL21 (Figure 5B).  PLCγ can mediate phosphorylation of ERK1/2 [92, 93].   To examine 
the contribution of ERK1/2 to activation of PLCγ1, we probed for PLCγ1 phosphorylation.  
Unexpectedly, we found that phosphorylation of PLCγ1 was decreased (Figure 5B).  From these 





Figure 4. Migration of primary cells to CCL21 on fibronectin. A) Migration of primary
naïve T lymphocytes to 0-400nM CCL21 on 5um membranes incubated in sfRPMI (n=3), p <
0.01. B) Migration of primary naïve T lymphocytes to 0-400nM CCL21 on 5um membranes

















Furthermore, PLCγ1 phosphorylation may be mediated by activated ERK1/2 to regulate CCL21 
mediated migration.    
     Cell migration requires regulated integrin adhesion, which is mediated by activation, followed 
by integrin de-adhesion [94, 95].  Therefore, we questioned the role of ERK1/2 in β1 integrin 
activation.  To this end we pretreated lymphocytes with UO126 or vehicle (DMSO) and 
measured levels of activated β1 integrins following activation with CCL21.  Lymphocytes were 
stained with an activation specific antibody, 12G10 [96].  Levels of activated β1 integrins were 
analyzed by flow cytometry.  We found that lymphocytes treated with UO126 displayed similar 
β1 integrin activation compared to controls (Figure 5C).   From this data we concluded that β1 
integrin activation in T lymphocytes in response to stimulation of CCR7 with CCL21 is not 
regulated by ERK1/2 phosphorylation. 
 
3.3.3  PLC is required for Migration on Fibronectin to CCL21  
  As mentioned, PLCγ1 binds to and activates β1 integrins [62].  Since loss of ERK1/2 
phosphorylation correlated with decreased PLCγ1 phosphorylation and reduced migration to 
CCL21, we questioned if PLC was necessary to control migration to CCL21.  To determine if 
PLC was necessary for migration, we used chemotaxis assays in the presence of U73122, a 
universal PLC inhibitor, or the U73343 control.  To confirm that U73122 blocked activation of 
PLCγ in T lymphocytes in response to CCL21 stimulation, we assayed for phosphorylation of 
PLCγ1 by western blot.  Lymphocytes pretreated with U73122 displayed decreased 
phosphorylation of PLCγ1.  In contrast, phosphorylation of ERK1/2 was increased compared to 
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Figure 5. Inhibition of ERK1/2 decreases migration of T lymphocytes to CCL21. Primary
naïve T lymphocytes were treated with 1uM UO126 or DMSO (control) for 90 minutes and were
migrated to 40nM CCL21across a membrane pre-incubated in 10μg/ml fibronectin. A) Cells
pretreated with UO126 migrated to CCL21 (n=3), p < 0.03. B) Cells stimulated with CCL21
probed for ERK1/2 and PLCγ1 phosphorylation and total (n=3). Densitometric analysis of
PLCγ1 and ERK1/2 was performed using ImageJ software. C) Cells were treated with UO126,







CCL21 was reduced (Figure 6A).  From these results we concluded that activation of PLC 
mediates migration of T lymphocytes to CCL21.   
 
 3.3.4  PLCγ1 is Necessary for β1 Integrin Migration and Activation  
 Because U73122 is a universal inhibitor of PLC, to determine the role PLCγ1 in the 
migration of naïve T lymphocytes via β1 integrins, we used PLCγ1 shRNA to specifically target 
and knock down levels of PLCγ1 in primary human T lymphocytes.  Lymphocytes were 
transiently transfected with PLCγ1 shRNA or control shRNA and assayed for migration and β1 
integrin activation.  We found that total PLCγ1 levels were reduced approximately 85% in the 
shRNA transfected lymphocytes (Figure 7A).  T lymphocytes that were depleted of PLCγ1 failed 
to migrate on fibronectin compared to controls (Figure 7B).  In addition, loss of PLCγ1 led to a 
failure to activate β1 integrins in response to stimulation with CCL21 as determined by flow 
cytometry (Figure 7C).  Since in response to U73122, we observed an increase in ERK1/2 
phosphorylation, we questioned if this was due to inhibition of PLCγ1.  Similarly, we observed 
that knock down of PLCγ1 resulted in a trend towards increased ERK1/2 phosphorylation 
compared to controls (Figure 7D and 7E).  From these results we concluded that PLCγ1 is 
required for transient ERK1/2 phosphorylation and activation of β1 integrins resulting in 
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Figure 6. Migration to CCL21, PLCγ1 and ERK1/2 phosphorylation is decreased upon
U73122 treatment. Primary naïve T lymphocytes were pretreated with 2.0uM U73122 for 20
minutes and migrated to 40nM CCL21 on membranes preincubated with 10μg/ml fibronectin. A)
Cells treated with U73122 were migrated on fibronectin to CCL21. (n=3), p < 0.03. B) Cells
stimulated with CCL21 were probed for PLCγ1 and ERK1/2 total and phosphorylation (n=3).






























Figure 7. PLCγ1 shRNA reduces migration to CCL21, β1 integrin activation and increases
ERK1/2 phosphorylation. Primary naïve T lymphocytes were transiently transfected (LipoD
293) with 8ug/ml PLCγ1 shRNA or control shRNA and incubated at 37°C, 5%CO2 for 72 hours
before use. A) Human primary T lymphocytes were depleted of PLCγ1 approximately 85% .
B) PLCγ1 knock down cells were migrated on fibronectin to 40nM CCL21 (n=3). p < 0.002.
C) β1 integrin activation (n=3), p < 0.03. D) Phosphorylation of ERK1/2 and PLCγ1 in
response to CCL21 stimulation. (n=3). E) Graphical Representation of western. Densitometric







3.3.5  Gαi Mediates Migration to CCL21  
To examine the signaling events upstream of PLCγ1 we investigated the role of G 
proteins in the activation of PLCγ1.  CCR7 couples to Gαi to initiate downstream signaling 
events and is required for migration to CCL21 [28].  Therefore, to examine signaling events 
more proximal to the membrane that mediates activation of PLCγ1, we pretreated lymphocytes 
with pertussis toxin.  As expected, lymphocytes pre-treated with pertussis toxin failed to migrate 
to CCL21 compared to controls (Figure 8A).  Therefore, to determine the role of Gαi in signaling 
through CCR7 to mediate activation of PLCγ1 and ERK1/2 in the presence of pertussis toxin, we 
assayed for changes in phosphorylation of PLCγ1 and ERK1/2.  In pertussis toxin treated 
lymphocytes phosphorylation of ERK1/2 and PLCγ1 was lost (Figure 8B).  These results 
indicate that CCR7 coupling to Gαi is necessary for activation of PLCγ1 and ERK1/2 mediated 
migration on fibronectin.  Furthermore, activation of Gαi is required to induce phosphorylation 
of both PLCγ1 and ERK1/2.   
     To determine the extent to which Gαi affects β1 integrin activation in naïve T lymphocytes, 
we pretreated lymphocytes with pertussis toxin, stimulated with 40nM CCL21 and assayed by 
flow cytometry for activated integrins on the cell surface.  We observed that loss of Gαi 
activation had no effect on β1 integrin activation, although cell migration to CCL21 was lost 
when compared to controls (Figure 8C).   Since cell migration requires control of integrin 
adhesion (activation) and de-adhesion (de-activation), from these studies we concluded that 
signaling through Gαi leads to cycling of adhesion and de-adhesion states.  These results suggest 
that Gαi is important for migration to CCL21, but not for the initial activation of β1 integrins in 
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Figure 8. Inhibition of Gαi decreases cell migration to CCL21, phosphorylation of ERK1/2
and PLCγ1 and β1 integrin activation. Cells were pretreated with 100ng/ml pertussis toxin for
2 hours and were migrated across a membrane incubated in 10μg/ml fibronectin to 40nM CCL21.
A) Cells were pretreated with pertussis toxin and migrated to 40nM CCL21 (n=3), p < 0.04. B)
Cells pretreated with pertussis toxin probed for total and phosphorylation of PLCγ1 and ERK1/2
(n=3). Graphical averages of three independent experiments. Densitometric analysis of PLCγ1
and ERK1/2 was performed using Image J software. C) Cells were stimulated with 40nM
CCL21, incubated with 3ug/ml 12G10 anti-human β1 antibody, labeled with anti-mouse FITC






3.4  Discussion 
 
     CCR7 is expressed on B lymphocytes, dendritic cells, natural killer cells, T regulatory cells 
and naïve T lymphocytes and is required for their migration into and within lymph nodes.  CCR7 
binds to two ligands, CCL19 and CCL21.  Although many studies have described CCL19 
signaling through CCR7, little is known about how CCL21 signals through CCR7 leading to 
migration [97-100].  Here we show that CCL21 stimulation of CCR7 leads to migration on 
fibronectin, which requires activation of Gαi and phosphorylation of PLCγ1 and ERK1/2. 
     High endothelial venules as well as lymph nodes express substantial amounts of fibronectin 
(1).  As lymphocytes enter into and migrate through lymph nodes they use β1 integrins for 
adhesion and migration (2).  Because CCL21 is required for lymph node entry as well as 
migration within the lymph nodes, we wanted to define the CCL21 mediated mechanisms that 
control β1 integrin-mediated migration on fibronectin.  In this study we provide evidence that 
CCL21 induces β1 integrin activation and promotes migration on fibronectin via PLCγ1 and 
ERK1/2 activation.  
     GPCRs are well known for their ability to activate MAPKs [52, 101].  MAPKs are involved 
in many cellular processes, including migration [102-104].  Several groups have reported that 
stimulation of CCR7 by CCL21 phosphorylates the MAPK ERK1/2 in primary murine T 
lymphocytes, B lymphocytes and HEK293 CCR7 transfected cells [46, 53, 54].  However, from 
these studies it is difficult to interpret what if any role ERK1/2 plays in migration of T 
lymphocytes.  In this study similar to previous studies, we report that ERK1/2 is rapidly and 
transiently phosphorylated in response to CCR7 activation by CCL21.  In addition, we find that 
ERK1/2 is required for migration to CCL21 via CCR7 on the β1 integrin ligand, fibronectin.  β1 
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integrin activation can result in ERK1/2 phosphorylation as a result of “outside in” signaling 
[105], however we also find that transient ERK1/2 phosphorylation can mediate migration to 
CCL21 via CCR7 by signaling to β1 integrins by “inside out” signaling.  
     Transient activation of ERK1/2 has been shown to be important for aortic smooth cell 
migration [55].  We used the MEK inhibitor UO126, to demonstrate that phosphorylation of 
ERK1/2 is important for T cell migration in response to CCL21.  In addition, using PLCγ1 
shRNA, we found that ERK1/2 phosphorylation was sustained which correlated with decreased 
migration to CCL21. Taken together, these results suggest rapid phosphorylation followed by a 
rapid decrease in phosphorylation of ERK1/2 is important for migration to CCL21 in T 
lymphocytes.   
     Stimulation of human epidermoid carcinoma cells with 12 (S) HETE results in PLCγ1 
phosphorylation and downstream activation of ERK1/2 via pertussis toxin sensitive signaling 
events [106].  In our study we found that transient phosphorylation of ERK1/2 is lost following 
reduction of PLCγ1 levels, suggesting that PLCγ1 contributes to the transient phosphorylation of 
ERK1/2.  Taken together we determined that not only is ERK1/2 important for migration, but 
PLCγ1s also important for regulating states of ERK1/2 activation.  These states of ERK1/2 
activation may also play an important role in β1 integrin de-activation.   
     As mentioned, cell migration requires regulated integrin adhesion (activation) followed by de-
adhesion (in-activation).  Interestingly, we found that Gαi activation was not necessary for β1 
integrin activation however, pertussis toxin inhibited migration to CCL21.  Similarly, we found 
that UO126 also had no effect on β1 integrin activation, but also inhibited migration to CCL21.  
Because pertussis toxin inhibited phosphorylation of ERK1/2, we speculated that Gαi and 
ERK1/2 are not required for the initial activation of β1 integrins, however they are required for 
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de-adhesion (in-activation) of β1 integrins, which leads to the loss of migration as seen with 
pertussis toxin and UO126.  Depleted PLCγ1 resulted in increased and sustained ERK1/2 
phosphorylation suggesting that it is the de-phosphorylation of ERK1/2 that is important for β1 
integrin recycling and migration to CCL21.  
         T lymphocytes are crucial mediators of inflammation, autoimmune disorders, allergic 
disease and cancer.  Migration is not only important for a normal functioning immune system, 
but also important in disease. Therefore, it is important to understand the molecular mechanisms 
of how T lymphocytes migrate into and throughout lymph nodes to become effector cells to 
carry out immune responses in the periphery.  This study is an important step in further 
understanding the molecular mechanisms of how T lymphocytes migrate to CCL21 and therefore 
could provide identification of inhibitors that could specifically target T cell entry and migration 
within lymph nodes in order to regulate the immune response. 
 
3.5  Experimental Procedures 
 
3.5.1  Mice, Primary Human Lymphocytes and Reagents 
C57BL/6 mice were purchased from Jackson Labs.  Primary human T lymphocytes were 
isolated from volunteer donors under an approved protocol, in accordance with policies and 
procedures of the human subjects protection program at the University of Kansas Medical 
Center.    UO126 (Calbiochem), U73122 and U73343 (Biomol) and pertussis toxin (List 
Biological Laboratories, Inc), human PLCγ1 shRNA (Origene) and species specific CCL19 and 
CCL21 (R&D) were purchased.  12G10 anti human activated beta 1 integrin antibody was 




3.5.2  T Lymphocyte Isolation 
Murine splenocytes were harvested and purified by negative selection (EasySep).  Human 
blood was collected from volunteer donors and peripheral blood mononuclear cells were isolated 
by Ficoll-paque (GE Healthcare Life Sciences) gradient.  Whole blood was transferred to 50ml 




(Cellgro).  In a separate 50ml 





centrifuged for 20 minutes at 2,000rpm without the brake.  The middle layer containing 
lymphocytes was removed, washed and pelleted.  The cell pellet was resuspended in 2ml of 
ACK lysis buffer (Lonza), incubated for 5 minutes at 37°C then rinsed with PBS.  T 
lymphocytes were negatively selected by EasySep kit (Stemcell Technologies) according to 
manufacturer’s protocol.  Lymphocytes isolated from C57BL6 mice or human donors were 
maintained in RPMI-1640 (Invitrogen), 10% heat inactivated fetal bovine serum (Hyclone), 2nM 
L-glutamine (Invitrogen) in a humidified atmosphere at 37°C and 5% CO2 for use within 3 days 
of isolation.   
 
3.5.3  Chemotaxis Assays   
All chemotaxis assays were carried out using a 48 well chemotaxis chamber 
(Neuroprobe).  Lower wells were loaded with 0-400nm of CCL21 in serum free RPMI-1640 
(sfRPMI) and were separated from the upper wells, which contained lymphocytes, by a 5 µm 
pore-nitrocellulose (Neuoprobe) membrane that had been pre-incubated in either sfRPMI or 
10µg/ml fibronectin (Sigma).  C57BL6 splenocytes or primary human T lymphocytes (5x10
5
) 
were migrated across the nitrocellulose membrane in a humidified, 37°C, 5% CO2 chamber for 2 
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hours to gradients of CCL21.  Chambers were disassembled, lymphocytes in the bottom chamber 
were collected, fixed in 2% paraformaldehyde and counted by hemacytometer.  Assays were 
performed in duplicate and replicated 3 times. 
 
3.5.4  Western Blots 
 Lymphocytes were pre-treated in serum free media with either UO126 (1μM) for 90 
minutes, U73122 (2μM) for 20 minutes or pertussis toxin (100ng/ml) for 2 hours at 37°C.  
Lymphocytes were then stimulated with 10nM CCL19 or CCL21 for 0,2,5,7, and10 minutes. 
Lymphocytes were lysed in radio immunoprecipitation assay buffer (RIPA) (100mM Tris pH 
8.0, 150mM NaCl, 2% Nonidet P40, 1% sodium deoxycholate, 0.2% SDS) supplemented with 
protease inhibitor cocktail (Sigma), 1mM sodium ortho-vanadate, 1mM sodium pyrophosphate, 
10mM sodium fluoride (Sigma) and 1mM β-glycerophosphate (Sigma) for 15 minutes on ice.  
Lysates were sheared and insoluble material removed by centrifugation @ 14,000 x g for 20 
minutes.  Supernatants (5x10
5
 cell equivalents per timepoint) were mixed with Laemmli sample 
buffer, fractionated on 7.5% SDS poly acrylamide gels and transferred to PVDF membranes.  
Membranes were pre-incubated in 5% milk/Tris buffered saline (50mM Tris-HCl pH7.5, 
150mM NaCl) 0.1% Tween-20 (TBST) or 5% BSA/TBST (Sigma) and probed with anti-
phospho ERK1/2, anti-total ERK1/2, anti-total PLCγ1 or anti-phospho PLCγ1 (Cell Signaling 
Technologies).  Primary antibodies were detected with HRP-conjugated anti species specific IgG 
(Pierce) and immune complexes were visualized with chemilluminence Supersignal West Femto 
(Pierce).  Membranes were stripped using Blotfresh (Blotfresh (Signagen)), rinsed in 1X TBST, 





3.5.5  PLCγ1shRNA Transfection  
Primary human T lymphocytes were transiently transfected with PLCγ shRNA or control 
shRNA using LipoD293 according to manufacturers’ instructions (Signagen). Briefly, in separate 
tubes PLCγ1 and control (8μg) shRNA were diluted into DMEM.  In a second set of tubes 
LipoD293 was diluted into DMEM.  Diluted LipoD293 was added to the diluted shRNA, 
incubated for 15 minutes and the LipoD293 complexes were added to the lymphocytes.  
Lymphocytes were incubated with the complexes in complete media for 72 hours at 37°, 5%CO2 
before use in assays.      
 
3.5.6  Beta 1 Integrin Activation Assay   
Lymphocytes were treated with UO126, pertussis toxin or transfected with PLCγ1 
shRNA as described previously.  Lymphocytes were unstimulated (0 minutes) or stimulated (2 
minutes) with 10nM CCL19 or CCL21.  Following stimulation lymphocytes were submerged 
into 1ml of ice cold 1X PBS.  Lymphocytes were labeled with 10μg/ml 12G10 on ice for 30 
minutes, washed in 1X PBS two times, incubated with fluorescein isothiocyanate (FITC) 
conjugated anti-mouse secondary antibody (Jackson Laboratories) for 30 minutes and washed in 
1X PBS two times.  Lymphocytes were fixed in 2% paraformaldehyde and analyzed by the 
FACS Calibur. 
 
3.5.7  Statistics 
All migration and β1 integrin activation assays are shown as two tailed, unpaired 
student’s t test.  A p value of <0.05 was considered statistically significant.   
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CHAPTER 4 - CCR7/CCL19 MEDIATES T LYMPHOCYTE EXPRESSION OF EDG-1 
 
4.1  Abstract 
 
T cells continually cycle between the blood, tissues and lymph to carry out immune 
surveillance and to mediate inflammatory responses.  While CCR7 controls lymphocyte 
recruitment to lymph nodes, its role in the egress of cells from the lymph nodes remains 
unexplored.  Here, we report a critical role for CCR7 and its ligand CCL19 in activating 
extracellular regulated kinase 5 (ERK5) and up-regulating the endothelial differentiation gene 1 
(EDG1) transcription factor Kruppel-Like factor 2 (KLF2) in naïve T cells.  Further, we 
demonstrate that exit of thymocytes from the thymus induces expression of EDG1, since this 
migration is inhibited in the presence of FTY720.  Using shRNA to knock down expression of 
ERK5 we demonstrate that signaling from CCR7 is required to induce EDG1 expression, and 
therefore exit of T cells from the lymph nodes. Thus, we define a novel signaling pathway which 
regulates T cell migration via CCR7/CCL19.  
 
4.2  Introduction 
 
 Following maturation, naïve T cells exit the thymus, travel through the circulation and 
enter lymph nodes via high endothelial venules (HEV) [107]. Well-defined immunological 
events that control T cell trafficking to and through lymph nodes are regulated by selectins, 
integrins, and chemokine receptors [108, 109]. Lymph node entry is mediated primarily via 
chemotaxis of C-C Chemokine receptor 7 (CCR7) expressing naïve T cells to CCL21 [31, 35], a 
38 
 
chemokine which is expressed along the HEV. In addition to CCL21, cells expressing CCR7 
respond to CCL19. Stromal cells within the T zone express both CCL19 and CCL21, while 
CCL19 is also expressed on mature dendritic cells [16, 110, 111]. Although both ligands are 
found in different regions of lymph nodes, physiologically distinct roles for each of the ligands 
remain mostly undefined. Recent studies by our laboratory and others, however, have revealed 
that T cells respond differentially to CCL19 and CCL21 [112-115]. 
 Studies to define roles for CCL19 and CCL21 have been carried out in paucity of lymph 
node T cell (plt) mice, a spontaneous mutant that lacks functional CCL19 and CCL21 [31, 116, 
117].  The absence of both ligands makes it difficult to discriminate specific, individual functions 
for CCL19 or CCL21.  Therefore, as expected, the phenotype of the plt mouse is similar to that 
of the CCR7
-/-
 mouse [29].  Further efforts to define individual roles for CCR7 ligands have used 
ectopically expressed CCL19 or CCL21 and have revealed that CCL21 promotes lympho-
neogenesis more efficiently than CCL19 [35, 113]. More recently the CCL19
-/-
 mouse, in which 
the CCL19 locus has been homozygously deleted, appeared normal, although there was a 
statistically significant increase in the number of lymphocytes in the lymph nodes of the CCL19
-
/-
 mouse when compared to a congenic wild type strain [34]. Similarly, adoptively transferred 
cells were trapped in the lymph nodes of mice treated with the CCL19 specific antagonist ELC8-
83 [36]. Normally, T cells exit the lymph nodes via the endothelial differentiation gene 1 (EDG-
1), a receptor for sphingosine-1 phosphate [65]. Because in the absence of CCL19 stimulation T 
cells fail to exit the lymph nodes, it was unclear whether the CCR7 receptor could be involved in 
regulating egress of cells from the lymph nodes via EDG-1. In contrast, the role of CCL21 
appears to be lymph node recruitment, since in the presence of a CCL21-specific antagonist, T 
cells failed to migrate to secondary lymphoid organs [37]. 
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 In T cells, transcription of EDG-1 is regulated by the Kruppel like factor 2 (KLF-2) [118] 
while expression of KLF-2 is thought to be regulated by extracellular regulated kinase 5 (ERK5) 
[68].   ERK5 (Big-Mitogen Activated Protein Kinase 1 (BMK1)) belongs to the mitogen-
activated protein kinase (MAPK) family of serine/threonine protein kinases.  ERK5 contains a C-
terminal trans-activation domain that allows it to directly regulate [119, 120] the myocyte 
enhancing factor 2 (MEF2) family of transcription factors [121]. Via MEF2 transcription factors, 
ERK5 promotes transcription of KFL2[68] and KLF2 is required for the expression of EDG1 
[118]. How this signaling pathway is regulated in T cells once they enter the lymph node is 
unknown.  
 In this manuscript, to characterize the signaling events that control EDG-1 expression we 
used the human HuT78 T cell line to examine the contribution of CCL19 to the regulation of the 
expression of EDG-1.  Examination of this pathway revealed that CCL19 mediates activation of 
the extracellular regulated kinase 5 (ERK5), which leads to increased levels of expression of 
Kruppel-like factor 2 (KLF2). Following prolonged stimulation with CCL19 we observed 
increased migration of cells to EDG-1. Knockdown of ERK5 expression by shRNA inhibits 
KLF2 expression, and results in a loss of migration to S1P. We used murine primary T cells and 
targeted siRNA to confirm this pathway in vivo.  To determine if CCL19 expression by activated 
dendritic cells, mediates recruitment of naïve T cells and the resultant expression of EDG1, we 
blocked signaling via CCL19 by using CCL19 shRNA on activated dendritic cells in vitro and a 
CCL19 antagonist, ELC8-83 in an adoptive transfer assay, in vivo [36].  We found that in the 
absence of CCL19, ovalbumin-primed dendritic cells failed to form conjugates with ovalbumin 
specific T cells in vitro. In vivo, in the presence of the CCL19 antagonist, naïve T cells failed to 
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up-regulate EDG-1 and therefore did not leave the lymph nodes. Taken together, these studies 
define a novel pathway in which CCL19 activates up-regulation of EDG-1.   
 
4.3  Results 
 
4.3.1  CCL19 Stimulation of Thymocytes Leads to EDG1 Mediated Migration  
 In fetal thymic organ cultures, migration of thymocytes from the thymus requires a 
minimum of eight hours stimulation with CCL19. The thymocytes do not migrate to CCL21.  In 
contrast, thymocytes dissociated from these fetal thymic organ cultures migrate robustly to both 
CCL19 and CCL21 during a 90 minute chemotaxis assay in transwells, in vitro [122]. Since the 
migration from the intact fetal thymic organ cultures in response to stimulation with CCL19 is 
delayed for eight hours, we hypothesized that this migration is promoted by transcriptional up-
regulation of a second protein(s).  EDG-1 is a candidate protein, since it is required for migration 
of thymocytes from the thymus [65] and the ligand for EDG-1, sphingosine-1 phosphate, is at a 
concentration of about 100nM in [123] fetal thymic organ culture media.  This concentration is 
sufficient to induce EDG-1 migration of primary T cells [65].  To examine the role of EDG-1 in 
CCL19 induced migration of T cells, we used fetal thymic organ cultures, treated with the EDG-
1 receptor antagonist FTY720 [65, 124] (Figure 9A). Antagonizing the EDG1 receptor with the 
FTY720 blocked T cell migration in response to stimulation with CCL19, and the migration of 
these thymocytes to CCL19 was reduced to the level of the cells treated without ligand (Figure 
9B). These studies demonstrate that treatment of fetal thymic organ cultures with CCL19, leads 





Figure 9.Thymic migration of T cells to CCL19 can be blocked by FTY720. A.)
Representative migration assay of day 15.5 thymus. B) Inhibition of migration of
















4.3.2  Activation of CCR7 via CCL19 but not CCL21 Leads to Phosphorylation of ERK5 
Our attempts to block the migration of fetal thymocytes via retroviral transduction of the 
fetal thymic organ cultures were thwarted, since transduction with the control virus, led to an 
increase in ERK5 and a concomitant increase in the number of cells that migrated to CCL19 
(data not shown). Therefore, to define the CCR7/CCL19-regulated signaling events in T cells, 
we used the CCR7 expressing human T cell line, HuT78[112].  To determine if EDG1 was up-
regulated in the HuT78 human T cell line following stimulation with CCL19, we examined 
HuT78 migration to 10nM sphingosine-1-phosphate following stimulation with 100nM CCL19 
or CCL21 for 24, 48, 72 or 96 hours. Only in response to CCL19 did we observe migration at 48 
and 72 hours (Figure 10A).  In the presence of CCL21 cells migrated to the same extent as the 
controls.  Semi-quantitative RT-PCR was used to measure levels of EDG1 expressed.  Following 
stimulation of cells in vitro for 48, 72 and 96 hours with 100nM CCL19, EDG1 mRNA was 
expressed (Figure 10B).  In the presence of CCL21, HuT78 showed a slight increase in EDG1 
expression, which was quickly reduced to below background levels (Figure 10B).  From these 
results, we concluded that following a 48-96 hour exposure of HuT78 T cells to CCL19 EDG1 
was up-regulated. 
 Expression of EDG-1 is regulated by KLF2 [118].  To examine the contribution of KLF2 
to the expression of EDG-1 in HuT78 cells following stimulation with CCL19, we used western 
blots.  Following stimulation with CCL19, KLF2 levels increased over 72 hours (Figure 11A).  
This increased level of expression correlated with increased expression of EDG-1.   To confirm 
that this signaling pathway was active in primary T cells we stimulated splenic T cells with 
CCL19 or CCL21 (Figure 11B), in culture for 24, 48, 72 or 96 hours. Expression of KLF2 
increased in primary T cells following exposure to CCL19 but not in response to CCL21.  Since  
43 
 
Figure 10. CCL19 stimulation of HuT78 T cells induces expression of S1P1 and
migration to sphingosine 1 phosphate. A) HuT78 cell migrate to sphingosine 1 phosphate
after 48 and 72 hours of stimulation with 200nM CCL19 but not CCL21. B) Treatment of
















Figure 11. KLF-2 is increased in response to CCL19 treatment. A) Stimulation of
HuT78 T cells with CCL19 mediates strong up-regulation of KLF2. B) Stimulation of



















KLF2 is a transcription factor for EDG-1[118], this observation demonstrated that CCL19 
activation of CCR7 led to increased levels of KLF2. 
 Extracellular regulated kinase 5 (ERK5) has a controversial role in up-regulating the 
expression of KLF2 [68, 125].  To determine if ERK5 is involved in up-regulating EDG-1 
following activation of T cells by CCL19, we wanted to determine if stimulation with CCL19 
could mediate activation of ERK5.  Activation of ERK5 can parallel activation of ERK1/2 [126, 
127]. In addition, in heterologous systems, CCL19 induced a four-fold increase in activation of a 
ERK1/2 when compared to ERK1/2 phosphorylation levels induced by CCL21 [49].  To 
determine if CCL19 preferentially activated ERK1/2 in T cells that express an endogenous 
CCR7, we compared activation of HuT78 by CCL19 to activation by CCL21 (Figure 12A).  We 
observed a transient increase in the phosphorylation of ERK1/2 in the presence of CCL19. In the 
presence of CCL21 we observed a loss of ERK1/2 phosphorylation when compared to un-
stimulated cells. To confirm the signaling event in primary cells we used mouse splenic T cells 
(Figure 12B).  We observed that while CCL21 failed to mediate ERK1/2 phosphorylation in 
primary murine T cells or in the HuT78 cell line, CCL19 mediated activation of ERK1/2 within 
5 minutes of stimulation. While at early time-points ERK1/2 was phosphorylated, we were 
unable to detect activation of ERK5 during this interval (data not shown).  As observed in 
macrophages, in T cells ERK5 runs as a 115kDa band [126]. Because up-regulation of KLF2 and 
the EDG1 receptor takes place over four days we examined the phosphorylation of ERK5 in the 
presence of CCL19, over 96 hours.  After 48 hours of stimulation of HuT78 T cells with CCL19 
we observed an increase in ERK5 phosphorylation, which was maintained through 96 hours of 
stimulation (Figure 13A).  ERK5 was also phosphorylated in cells treated with CCL21, but to a 
lesser extent. In primary T cells, however, levels of ERK5 increased and ERK5 was  
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Figure 12. ERK1/2 is phosphorylated in response to CCL19. A) Stimulation of
HuT78 human T cells with CCL19 but not CCL21 leads to phosphorylation of p44/42, 0-
5 minutes. B) Stimulation of Hut78 human T cells with CCL19 but not CCL21 leads to
















Figure 13. ERK5 is phosphorylated in response to CCL19. A) HuT78 T cell
line induce ERK phosphorylation following activation with CCL19. B) Primary


















phosphorylated only in the presence of CCL19 and not in the presence of CCL21 (Figure 13B).  
We concluded that in primary cells CCL19 differentially up-regulated ERK5. 
 
4.3.3  CCL19 Expression by Activated Dendritic Cells Mediates Recruitment of Naïve T Cells  
A likely source of CCL19 is mature dendritic cells, and since CCL19 mediates 
chemotaxis of CCR7 expressing cells, [128] to examine the contribution of CCL19 to the 
generation of conjugates between naïve T cells and activated dendritic cells we used an in vitro 
conjugate assay.  To this end, CD11c+ bone marrow derived dendritic cells (BMDC) (Figure 
14A) loaded with ovalbumin and matured in the presence of tumor necrosis factor alpha (TNF) 
were incubated with naïve OTI cells, which express a transgenic T cell receptor (TCR).  Under 
these conditions, we observed a mean of 28% T cells formed conjugates with antigen primed T 
cells when dendritic cells were treated with control shRNA.  In contrast, in the presence of 
CCL19 shRNA (Figure 14B), the numbers of conjugates was significantly reduced  (p=0.030) 
(Figure 14C).  We concluded that CCL19 expressed by dendritic cells mediated the generation of 
conjugates between naïve T cells and activated dendritic cells.   
 
4.3.4  In the Absence of ERK5 Naïve T Cells Failed to Exit the Lymph Nodes  
Previous studies by other labs have used adoptive transfer assays to demonstrate that T 
cells have a reduced ability to migrate via CCR7 as they up-regulate EDG-1[65] in response to 
antigen exposure.  This reduced migration is likely a result of exposure to CCL19, which rapidly 
internalizes ~80% of CCR7 [112, 115] since exposure to CCL21 leads to internalization of only 
~25% of available CCR7. Since homozygous deletion of ERK5 is embryonic lethal [119, 129, 
130] to confirm the ERK5 signaling was required to induce the EDG-1 expression following  
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Unstained            Isotype                  CD11c
452   Control
CCL19
Figure 14. CCL19 knockdown results in inhibition of dendritic cell/T cell
conjugate formation. A) Isolation and purification of primary murine dendritic cells
indicated by expresssion of CD11c by flow cytometry. B) Confirmation of knock
down of CCL19 by viral transduction. C) Loss of CCL19 expression in dendritic cells













activation of T cells with CCL19, we used ERK5 specific siRNA.  Splenic and lymph node T 
cells were nucleofected with ERK5 siRNA, cultured for 2 days, labeled with CSFE and 
transferred to wild type hosts.  The wild type hosts were immunized with ovalbumin, and 96 
hours later, adoptively transferred CSFE+ V5+ cells were isolated by flow cytometry from 
draining lymph nodes and assayed for EDG-1 in a migration assay to 10nM S1P.  Both OTI and 
OTII cells were retained in the lymph nodes (Figure 15A and 15B). Cells treated with control 
siRNAs expressed EDG-1 and migrated to S1P (Figure 15C).  In contrast, cells treated with 
ERK5 siRNA failed to migrate to EDG-1.  We concluded that signaling within the lymph node 
induces expression of EDG-1 via ERK5 and KLF2.  
 
4.4  Discussion  
 
The differential roles for CCL19 and CCL21 in the behavior of T cells have been elusive.  
In this study, we described a novel signaling pathway that differentiates signaling from CCL19 
and CCL21 in T cells. The results in this paper lead to the model shown in Figure 8.  We have 
found that CCL19/CCR7 activation mediates phosphorylation of ERK5, and in turn, up-
regulation of KLF2. In response to increased levels of KLF2 the expression of EDG1 increases. 
Our model is supported by the lymph node distribution of CCL21 and CCL19 and the extent of 
internalization of CCR7 following engagement of these two ligands. We and others have shown 
that only ~20% of CCR7 is internalized when it is bound to CCL21, allowing for CCR7 to 
remain on the surface of the cell and continue to sense CCL19 or CCL21 in the lymph node. We 
speculate that if the T cell fails to make a conjugate with a dendritic cell that lasts for more than 
an hour, the signaling pathway is not turned on, allowing the T cell to  
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Figure 15. Loss of ERK5 results in T lymphocyte retention in lymph nodes. A)
Loss of ERK5 expression prevents exit of CD4 T cells from lymph nodes. B) Loss
of ERK5 expression prevents exit of CD8 T cells from lymph nodes. C) Loss of














maintain its level of EDG-1 receptor and exit the lymph nodes.  In contrast, if the T cell forms a 
conjugate with an activated dendritic cell, that expresses a cognate ligand the T cell recognizes, it 
maintains the close contact required to internalize over 80% of CCR7 and to activate ERK5.   
Studies are ongoing within our lab to determine what cytoplasmic adaptors are required for 
activation of ERK5. 
 We initiated our studies with thymic migration studies. Recent studies have reported that 
thymic dendritic cells regulate the evolution of regulatory T cells in the thymus [131].  These 
dendritic cells which are recruited from the periphery would express high levels of CCL19.  
Initially, CCL19 was described as a chemokine that directed the emigration of newly generated 
thymocytes from the thymus [108]. By in vitro assays, migration of dissociated thymocytes was 
equivalent when comparing CCL21 and CCL19. It was unclear however, why thymocytes 
exiting the thymus, migrated from the thymus only after an eight-hour exposure to CCL19, but 
not to CCL21. This delayed migration to CCL19, led to our hypothesis that transcriptional up-
regulation of specific genes was required to regulate the expression of a second receptor that 
could be used for migration from the thymus.  This implicated the existence of a second receptor 
that was used for emigration of cells from the thymus. Interestingly, two years later, studies 
examining the role of EDG-1 in thymocyte emigration, revealed EDG-1 as a possible candidate 
receptor.  
As mentioned, CCL19 induces internalization of 80% of the CCR7 on the cell surface. In 
contrast, CCL21 induces internalization of ~20% of the cell surface CCR7.  Therefore, it is 
possible that the differential signaling is due to differences in levels of CCR7 on the surface.  
Such a hypothesis would be difficult to test without generating numerous T cell lines that express 
different levels of CCR7 on the cell surface.  An alternative explanation is that internalization of 
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CCR7 via CCL19 vs. CCL21 mediates recruitment of different adaptor proteins that remain 
associated with the cytoplasmic face of the receptor following recycling of the receptor. We have 
observed that internalization of CCL19 bound CCR7 mediates recruitment of arrestin 3, while 
CCL21 does not. Since CCL19 mediates internalization of CCR7 through arrestins, while 
CCL21 does not[112], it is possible that the activated form of CCR7 recruits ERK5 following 
engagement of CCL19 via arrestins. The recruitment of arrestins takes place within 5 minutes of 
CCR7 activation by CCL19, and while ERK1/2 is activated within this timeframe, activation of 
ERK5, requires a minimum of one hour of exposure to CCL19.  From this observation, we 
speculate that other adaptors may be required, that associate only after CCR7/CCL19 has 
trafficked within the cell to sites that allow for recruitment of these adaptors.  The adaptors 
would then remain associated when the receptor recycles. In contrast, signaling through 
CCR7/CCL21 fails to activate this pathway since it takes a different pathway when it is 
internalized [46, 49, 112, 114].  If the receptor is re-internalized rapidly, due to the presence of 
ligand the subsequent internalizations may recruit novel adaptors, to the already modified 
cytoplasmic tail.  At some point ERK5 associates with the activated receptor and is internalized.  
CCR7 has been observed in the nucleus in some cells [71].  A function for CCR7 in the nucleus, 
however has not yet been defined. 
 Since the ERK5
-/-
 mouse is embryonic lethal, we were unable to use the T cells from that 
mouse to study ERK5 signaling in the absence of ERK5.  Therefore, we used ERK5 siRNA to 
reduce expression of ERK5 in primary T cells.  This allowed us to examine signaling via 
CCR7/CCL19 in the absence of ERK5. From our studies, we concluded that ERK5 is indeed 
required for up-regulation of EDG-1.  These results are supported by reports in which a CCL19 
specific antagonist was used to block signaling through CCR7/CCL19.  In this study, following 
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pre-treatment of mice with the CCL19 antagonist ELC8-83, the mice were injected with T cells 
expressing the ovalbumin TCR, and stimulated with ovalbumin.  In support of our studies, ELC8-
83 prevented egress of T cells from the lymph nodes.  More recently, T cells adoptively 
transferred to a CCL19
-/-
 mouse, failed to leave the lymph nodes [34]. In these studies and in our 
studies, loss of signaling through CCR7/CCL19 blocked egress of T cells from the lymph nodes.   
 KLF2 expression is tightly regulated in T cells during differentiation and maturation. 
Over-expression of activated ERK5 leads to up-regulation of KLF2 in a reconstituted fetal 
thymic organ culture, while dominant negative ERK5 blocks KLF2 [119] . Recently it was 
reported that Foxo1, one of four members of the Foxo subfamily of transcription factors, that 
control life span cell cycle progression and [132, 133] apoptosis, controls the expression of 
CCR7 and KLF2[133]. In these studies, in response to homozygous deletion of a floxed Foxo1, 
in a CRE/lox mouse, the levels of CCR7 were reduced along with the levels of KLF2. In other 
studies, using a microarray of RNA’s enriched for immune function, KLF2 mRNA levels were 
found to be up-regulated during positive selection at the same time when CCR7 is first expressed 
in T cells [134] in the thymus and lymph nodes. This was not surprising, given the role that 
CCR7 has in the up-regulation of KLF2. Furthermore, KLF2 levels increase following in vitro 
stimulation of naïve T cells, with IL-2 or IL-17 [135]. KLF2 expression correlated with long 
term survival.  
 ERK5 activation has been associated with Src activation and the increased migration of 
fibroblasts by mediating changes in the actin cytoskeleton, in particular mediating a loss of stress 
fibers [136, 137]. In addition, activation of ERK5 in fibroblasts promotes invasive phenotype of 
the cells and degradation of ECM [136].  In fibroblasts, transformed by activated c-Src or v-Src, 
ERK5 mediates podosome formation and the invasive behavior of cells, by regulating the 
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induction of matrix degradation. Since mature T cells leave the lymph nodes, and extravasate to 
sites of infection, it is questionable whether the observed change in ERK5 activation, reflects 
increased migratory potential.  In addition, we observed a decrease in the level of ERK1/2 
phosphorylation.  Since the levels of ERK5 phosphorylation are below our limits of detection, by 
western blot, it is unclear if along with pERK1/2, ERK5 phosphorylation levels decrease 
following exposure to CCL21. Such a decrease could slow matrix degradation and extravasation 
of cells into the tissues.   We observed an increase in the level of EDG-1 expressed in T cells 
over the 96 hour CCL19 stimulation period making it difficult to determine if there were any 
changes in the overall migration potential of the cells to EDG-1 over the time course.  At present, 
studies are underway in our laboratory to examine the role of ERK5 in regulating migration in 
CCL19 activated T cells to chemokines other than CCL19 and CCL21. 
 ERK5 plays roles in cell proliferation, survival and differentiation [126, 138-144].  In a 
macrophage cell line, and in primary human macrophages ERK5 phosphorylation in response to 
signaling through the CSF-1 receptor, mediates proliferation [126].  This proliferation is linked 
to signaling through c-jun, which correlates with translocation of ERK5 into the nucleus. Our 
studies measured ERK5 phosphorylation in the presence of 40nM CCL19 or CCL21. T cells that 
lacked expression of CCR7 had reduced proliferation [145]. It is tempting to speculate that a 
possible role for activation of ERK5 in response to a CCL19 rich dendritic cell, would be to help 
to promote proliferation of the activated T cell. 
 In conclusion, our data defines differential signaling events that take place within naïve T 
cells following activation by CCL19 or CCL21. This signaling information may be used to 
combat a variety of diseases.  That CCL198-83 and m-SLC4 are CCL19 and CCL21 specific 
antagonists, which block lymph node entry and dendritic cell/T cell association, respectively, 
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may lead to the identification of pharmaceutical agents that specifically block lymph node entry 
or sampling of dendritic cells/exit from the lymph nodes. Such therapies could be important in 
treating autoimmune diseases, lymphoproliferative disorders or asthmas that have been linked to 
CCR7 [146-152]. 
 
4.5  Experimental Procedures 
 
4.5.1  Cell Lines and Mice   
The HuT78 human T cell line was purchased from ATCC and maintained in HuT78 
media (RPMI 1640 (Invitrogen)/10% heat inactivated fetal bovine serum (Hyclone) /2nM L-
glutamine (Invitrogen)) in a humidified atmosphere at 37°C and 5% CO2.  C57BL/6 mice were 
purchased from Jackson Labs. C57BL/6-Tg(OT-I)-recombination-activating gene 1 deficient 
(RagI
-/-
) mice were purchased from Taconic.  T lymphocytes isolated from OT-II.2a/RAG1 
C57BL/6 were maintained for up to one week in T cell media (RPMI 1640, 10% heat inactivated 





4.5.2  Fetal Thymic Organ Culture  
Thymic organ cultures were prepared as described [122], with the following 
modifications. Thymic lobes were removed from C57BL/6 fetuses at 15.5 days postcoitum, 
cultured at the air/media interface on 3µm
2
 transwell filter membranes in a humidified 
5%CO2/air incubator at 37°C.  Cultures were maintained in FTOC media ((RPMI1640 
(Sigma)/10% heat inactivated fetal bovine serum (Hyclone) /50µM -mercaptoethanol (Fisher), 
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2mM L-glutamine (Sigma), 1 x nonessential amino acids (Cellgro), 10mM HEPES (Cellgro), 
1mM sodium pyruvate (Cellgro), 100 U/ml penicillin (Cellgro), and 100µg/ml streptomycin 
(Cellgro)), for 5 days to allow for the development of thymocytes to a broad range of 
developmental stages that resemble the distributions of an adult thymus [122].  Thymic lobes 
were washed, placed on a fresh 3µm
2
 transwells (Millipore) for 2 days after adding 100nM of 
either murine CCL19 (R&D) or murine CCL21 (R&D) or FTY720 (Cayman). The number of 
cells that migrated to the lower wells were counted by hemacytometer.  
 
4.5.3  Chemotaxis Assays 
Chemotaxis assays were carried out as described[112].  For chemotaxis assays, Hut78 
cells were treated with 40 nM murine CCL19  (R&D), CCL21 (R&D) or an equal volume of 
vehicle (phosphate buffered saline (PBS)) for 96, 72, 48 and 24 hours and migrated across a 5um 
membrane (Neuro Probe, Inc.) at 37°C and 5% CO2 for 2 hours to 10nM S1P (Sigma) in serum 
free RPMI 1640 medium in a 48 well chemotaxis chamber.  Cells in the bottom chamber were 
counted by hemacytometer.  Assays were performed in duplicate and replicated 3 times. 
 
4.5.4  Dendritic Cell/T Cell Conjugates   
Bone marrow derived dendritic cells were generated from C57BL/6 wildtype mice as 
described[153].  Briefly, 2 x 10
6
 cells isolated from bone marrow were plated on bacterial petri 
dishes and cultured in 10 ml DC media (RPMI 1640, 10% heat inactivated fetal bovine serum, 
100µg/ml penicillin-streptomycin, 50µM β-mercaptoethanol, 20ng/ml murine granulocyte 
macrophage colony stimulating factor (GM-CSF) (R&D), and 2nM L-glutamine).  At 48 hours 
(Day3), 10ml of fresh DC media was added to each dish.  On days 6 and 8, 10ml of 
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supernatant/cells was removed, cells isolated by centrifugation (90 x g) and resuspended with 
fresh DC medium.  On day 9 non-adherent cells were collected and nucleofected using the Amax 
DC Nucleofection kit, Nuclefector II, and program Y-001 (Amaxa) with shRNA against CCL19 
(Origene).  10
6
 nucleofected cells were plated into each well of a 12 well dish and RNA knocked 
down for 48 hours.  On day 11 immature dendritic cells were labeled with (5uM) 5-(and-6)-
carboxyfluorescein diacetate, succinimidyl ester (CFSE) for 10 minutes at 37°C, washed, primed 
with 50ug/ml ovalbumin, and matured with 100ng/ml TNFα.   T cells were isolated from OT-
II2a/Rag1C57BL/6 spleens by passing spleens through a wire mesh.  T cells were purified using 
a negative selection, mouse T cell enrichment kit according to manufacturers’ directions 
(EasySep).  Purified T cells were labeled with (10uM) (5-(and-6)-(((4-
chloromethyl)benzoyl)amino)tetramethylrhodamine) CMTMR for 30 minutes at 37°C, washed 
and plated in the well with the ovalubumin-primed, CFSE labeled mature dendritic cells.  Cells 
were allowed for form conjugates for two hours, fixed and conjugates counted per 100 dendritic 
cells. 
 
4.5.5  Western Blots 
HuT78 and primary cells were counted by hemacytometer or following migration assays, 
whole thymic organ cultures were lysed in radio immunoprecipitation assay buffer (RIPA) 
(100mM Tris pH 8.0, 300mM NaCl, 2% Nonidet P40, 1% sodium deoxycholate, 0.2% SDS) 
supplemented with protease inhibitor cocktail (Sigma), 1mM sodium ortho-vanadate, 1mM 
sodium pyrophosphate, 10mM sodium fluoride (Sigma) and 1mM β-glycerophosphate (Sigma).  
Lysates were centrifuged for 20 minutes following homogenization.  5 x 10
5
 cell equivalents 
were solubilized in sample buffer with 10 mM dithiothreitol, fractionated on 10% SDS poly 
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acrylamide gels and transferred to PVDF membranes.  Membranes were incubated in 5% 
milk/Tris buffered saline (50mM Tris-HCl pH7.5, 150mM NaCl) 0.1% Tween-20 (TBST) and 
probed with anti-ERK5 (Cell Signaling Technologies), anti-α-tubulin (Cell Signaling 
Technologies), anti-β-actin (Cell Signaling Technologies), anti-KLF-2 (CeMines) or anti-MIP3β 
(AbCam).  To detect phospho-ERK5, membranes were incubated in 3% bovine serum albumin 
(Sigma #A3058) and probed with anti-phosphoERK5 (Upstate).  MIP3β was detected with HRP 
rabbit anti-goat IgG and all other antibodies were detected with HRP goat anti-rabbit IgG 
(Pierce) and immune complexes were developed with chemilluminence Supersignal West Femto 
(Pierce).  Protein bands were visualized with X-MAT film and quantified with a Fuji LAS-4000.  
Membranes were stripped using Blotfresh (Signagen) stripping buffer for 10 minutes 
(SignaGen), rinsed three times in TBST, blocked and re-probed.    
 
4.5.6  Reverse Transcriptase-PCR  
Total RNA was extracted from Hut78 cells or splenocytes using TRIzol (Invitrogen).  
cDNA was prepared as follows: 50ng random primers (Invitrogen), 1µg RNA, 0.25mM dNTP 
(TakaRa) and ddH2O, were heated to 65°C for 5 minutes and chilled on ice. 5X First Strand 
Buffer (Invitrogen) was added to the mixture and adjusted to 1X in the presence of 5 mM DTT 
(Invitrogen), and 40 U RNAse (Promega).  The reaction was incubated at 25°C for 2 minutes, 
and 200U Super Script II RT (Invitrogen) was added. The cDNA was primed at 25°C for 10 
minutes, and then extended by incubating at 42°C for 50 minutes. Super Script II RT was 
inactivated by heating to 70°C for 15 minutes.  To assay for expression, PCR was carried out by 
addition of 1x Green Go Taq flexi buffer (Promega), 1.5mM MgCl2 (Invitrogen), 0.25mM dNTP 
(TakaRa), 1U Taq DNA polymerase (Invitrogen), cDNA, H2O and mRNA specific primers.  
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Primers used: murine S1P1 [65] and murine β-actin forward: 
5’ATGACGATATCGCTGCGCTG3’ reverse: 5’AGTAACAGTCCGCCTAGAAG3’.  PCR 
products were resolved on a 2% agarose gel containing ethidium bromide. Products were 
amplified 30 cycles using a thermocycler. S1P1 and β-actin yielded products of the predicted 
size. 
 
4.5.7  Adoptive Transfer 
Adoptive transfers were carried out as described[65], with the following modifications. 
OT-II.2a/RAG1 C57BL/6 splenocytes were isolated and 2 x 10
7
 cells were Nucleofected 
(Amaxa) with ERK5siRNA or control siRNA (Ambion) in OptiMEM.  Endogenous ERK5 was 
knocked down for 72 hours, and labeled with 1µM 6-carboxyfluorescein diacetate succinimidyl 
ester (CFSE, Molecular probes)for 20 minutes at 37°C, rinsed and transferred intravenously to 
C57BL/6 recipients.  The day after transfer, (day 0), mice were immunized subcutaneously with 
a total of 200µg ovalbumin (Sigma) emulsified in complete Freund’s adjuvant (Sigma) (ratio 
1:1) at 4 sites along the back.  After 96 hours, mice were euthanized, and lymph nodes were 
analyzed for migration to sphingosine 1 phosphate, CCL19, CCL21 and for numbers of CSFE+ 
cells in lymph nodes, by flow cytometry and hemacytometer.  All assays were performed in 
duplicate for sphingosine 1 phosphate or chemokine and were repeated using cells from a 







CHAPTER 5 – EXPRESSION OF A CHEMOKINE RECEPTOR, CCR7, MEDIATES 
METASTASIS OF BREAST CANCER TO THE LYMPH NODES AND REDUCES 
METASTASIS TO THE LUNGS IN MICE 
 
 
5.1  Abstract 
 
The C-C chemokine receptor 7 mediates lymphocyte migration to lymph nodes in 
response to its ligand CCL21, where it regulates lymph node organization and proliferation. 
While CCR7 has been implicated in lymphocyte migration to lymph nodes, the molecular 
mechanism that mediates targeting of breast cancer metastasis to the lymph nodes has yet to be 
defined. To explore the mechanisms used by breast cancer to migrate to the lymph nodes, we 
used the MMTV-PyVmT mammary tumor cells (PyVmT).  In vitro we found that expression of 
CCR7 controlled migration of PyVmT mouse mammary tumor cell migration to CCR7 ligands 
as well as MDA-MB-231, MCF-7 and T47D human breast tumor cells.  To define a 
physiological significance for CCR7 regulation of migration, we used the PyVmT transgenic 
mouse model of metastatic breast cancer. When PyVmT cells transfected with control vector 
were orthotopically transferred to the mammary fat pad of FVB mice, there were significantly 
more lung metastasis (10/10 mice) but not to the lymph nodes (0/10), which repeated the known 
phenotype. In contrast, CCR7-transfected PyVmT (PyVmT-CCR7) cells transplanted to the fat 
pad metastasized to the lymph nodes (6/10 mice) but had a reduced rate of metastasis to the 
lungs (4/10 mice). These data show, for the first time, that expression of CCR7 in breast cancer 
62 
 
can target migration of breast cancer cells to the lymph nodes, and in the future may be used as a 
tool for studying lymph node.  
 
5.2  Introduction 
 
When a breast tumor has metastasized to more than four lymph nodes, a woman’s chance 
of surviving breast cancer is significantly reduced.  Consequently, clinical staging of breast 
cancer involves determining whether breast tumors have metastasized to the lymph nodes. It is 
puzzling however, that subsets of these women are long-term breast cancer survivors, even when 
breast cancer metastases have been detected within their lymph nodes.  A clue to the differences 
in survival rates among women may have been revealed when it was observed that in patients 
with C-C chemokine receptor 7 (CCR7) expressing breast tumors that had metastasized to the 
lymph nodes, tumor metastases were not found in the lungs, liver or brain, but instead were 
restricted to the surgically removable lymphoid organs [154].  
CCR7 is activated by binding either CCL19 or CCL21 [155, 156]. Under normal 
circumstances, naïve T cells use CCL21 to travel to and enter lymphoid tissues from the blood 
via high endothelial venules (HEV) and migrate through the T cell zone before returning to the 
circulation.  Naive T cells are activated when they migrate toward and interact with activated 
CCL19-expressing dendritic cells, then bind to the appropriate major histocompatibility/antigen 
complex[157]. CCL19 and CCL21 chemokines have important roles in establishing and 
maintaining the architecture [158] of the secondary lymphoid organs, where they coordinate the 
adaptive immune responses between dendritic cells, B-cells and T cells. Thus, chemokines are 
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critical mediators of the inflammatory response and may contribute to tumor cell lymph node 
localization in CCR7 expressing tumors.   
At present, it is thought that metastasis results from non-random events, where tumor cells 
target specific organs in response to unique factors found within the targeted organ [159]. These 
factors control tumor cell adhesion, migration and organ invasion.  Small (8-12KDa) chemotactic 
cytokines, termed chemokines have been recently identified as contributing to the metastatic 
behavior of tumor cells [72], but the specific functions regulated by chemokines like CCL19 and 
CCL21 that contribute to breast tumor metastasis have remained elusive.  During metastasis, a 
tumor cell must detach from the primary tumor, extravasate to the micro vessel walls, and 
migrate to the target tissue.  CCR7 regulates lymphocyte adhesion, migration and proliferation, 
and therefore is an important receptor to understand in the regulation of tumor metastasis.  
CCR7 is up regulated in certain breast cancers [72] and is associated with lymph node 
metastases [71]. In vitro MDA-MB-231 and MDA-MB-361 breast cancer cell lines and a 
primary sample from a patient were capable of migrating to CCL21.   To date, it remains unclear, 
whether CCR7 can promote migration of breast cancer from the mammary fat pad to the lymph 
nodes. We have adapted a mouse mammary tumor virus (MMTV)-PyVmT model of metastatic 
breast cancer, which selectively metastasizes to the lungs, to express CCR7 in the PyVmT cells 
to allow us to determine the role for CCR7 in breast cancer progression and metastasis.  We have 
observed that CCR7 directs the migration of metastasis to the lymph nodes, instead of the lung 
where PyVmT cells that lack CCR7 expression metastasize.  In addition, we have found that 
similar to its role in lymphocytes, CCR7 alters the differentiation state of PyVmT cells as 




5.3  Results 
 
5.3.1  CCR7 is Expressed on Human Primary Cells   
CCR7 is up-regulated on the surface or in the cytoplasm of cells histochemical preparations of 
tumors [71, 72, 154, 160, 161]. To determine whether CCR7 is expressed on the surface of breast 
cancer cells, we examined the expression levels of CCR7 in isolated epithelial cells by surface 
labeling with anti-CCR7 antibodies (n=5) and quantified by flow cytometry.  To this end primary 
cells were dissociated with collagenase and isolated by positive selection using magnetic beads 
that target epithelial cell markers.  We found that CCR7 was elevated on freshly isolated primary 
cells and CCR7 receptor was expressed in malignant breast epithelia as compared to normal.  
Even this difference in receptor expression levels can profoundly affect the cellular response to 
ligand binding [162].  
 
5.3.2  Generation of CCR7 Expressing PyVmT Cells   
We hypothesized that CCR7 is used by breast cancer to metastasize to the lymph nodes, a 
process that requires adhesion, cell spreading and migration.  To examine the effect of low levels 
of CCR7 on breast cancer cell adhesion, spreading and migration, we examined the effects of 
stimulating CCR7 in a murine breast cancer cell line PyVmT [158], which lacks endogenous 
CCR7 as determined by RT-PCR (data not shown).  To facilitate detection of CCR7 in PyVmT 
tumors in vitro we used a FLAG epitope fused to the N-terminus of CCR7 to generate transient 
transfectants that expressed N-FLAG-CCR7 (PyVmT-CCR7).  Transient transfection of the 
PyVmT cells resulted in a modest increase in the levels of murine CCR7 expression that were 
65 
 
similar to levels that we have observed in fresh tumor isolates from human breast cancer patients 
and (Figure 16).   
 
5.3.3  CCR7CCL19 Promotes Spreading of PyVmT Cells on Fibronectin  
Adhesion of tumor cells, via 1 integrins promotes tumor metastasis [85].  To determine 
if CCR7 expression affects cell adhesion, spreading or migration via 1 integrins we used in 
vitro assays.  Coverslips were coated with the 10µg/ml 1 integrin ligand fibronectin, and cells 
were allowed to adhere for 5 minutes or spread for an hour.  To confirm specificity for the 1 
integrins, we used a 1 integrin, function blocking antibody. Activation of CCR7 on PyVmT-
CCR7 cells had no effect on cell adhesion via the 1 integrins (Figure 17A).  In contrast, we 
observed that CCR7 promoted 1 integrin-specific cell spreading, in the presence of CCL19, a 
ligand for CCR7(Figure 17B). 
     
5.3.4  CCR7 Promotes Migration of Breast Cancer Cells to CCL19 and CCL21   
Following detachment and extravasation, an essential step in metastasis is migration of 
cells from the primary tumor to the site where the metastasis attaches and grows.  To determine 
if CCR7 can promote migration to CCR7 ligands, we used an in vitro transwell chemotaxis assay 
on 1 integrin coated surfaces.  We found that CCR7 preferentially promoted migration to 
CCL19 and CCL21 under these conditions (Figure 18A and 18B).  From these results we 
conclude that CCR7 can promote directed migration of cells to lymphoid organs in response to 





Isotype control    
CCR7 (M2)  
Figure 16. Transient transfection of PyVmT with N-FLAG-CCR7 results in low level of
CCR7 expression. PyVmT were transiently transfected with a N-terminally tagged murine
CCR7, dissociated from culture and assayed for expression of FLAG with an M2 antibody,
















Figure 17. CCR7 activation by CCL19 promotes spreading but not adhesion. A) PyVmT
cells were seeded onto fibronectin incubated coverslips in the presence of CCL19 and CCL21
+/- anti-β1 antibody and allowed to adhere. Number of cells were counted per 10X field. B)
PyVmT cells were seeded onto fibronectin incubated coverslips in the presence of CCL19 and











5.3.5  Development of PyVmT/FVB Mouse Model of Breast Cancer   
To examine the physiological significance of our in vitro observations, we used the 
PyVmT model [158], that has been shown to form tumors analogous to stage IV human breast 
cancer, making this an ideal model to study breast cancer progression.  The PyVmT tumor cells 
that were isolated had been selected for metastasis primarily to the lungs [158].  In the original 
study, 500,000 PyVmT tumor cells were implanted into the fifth mammary fat pad of syngeneic 
FVB mice and within forty two days, 100% of the mice uniformly developed tumors that 
metastasized only to the lung [158].  Previous studies, which examined the role of the CXCR4 
receptor in metastatic behavior of tumor cells, revealed that differences were observed in 
outcome between CXCR4 expressing tumors and vector controls only when low levels of tumor 
cells were seeded, [163]. Therefore, to determine the lowest number of PyVmT cells that could 
be used to generate tumors in the FVB mice, we compared the numbers of tumors generated 






 tumor cells.  In our studies 100% (6/6) of the 
animals with 10
6 
tumor cells developed palpable tumors within 24 days, 100% (6/6) of the 
animals with 10
5
 tumor cells developed tumors within 50 days, and 33% (2/6) of the mice 
developed tumors when 10
4
 cells were implanted (Table 1) .    




PyVmT-vector (CCR7 (-)) tumor cells 
into the fifth mammary fat pad of the FVB mice.  To obtain statistically significant data, we used 
10 mice per group.  Calipers were used to measure tumor length, width and height.  Tumor 






Figure 18. Stimulation of PyVMT-CCR7 cells with 40nM CCL19 or 40nM CCL21
promotes migration when compared to PyVMT-pcDNA3.1 controls. A) Graphical
representation of PyVmT migration to CCL19 or CCL21 on fibronectin-coated membranes
(10g/ml). After 3 hours migrated cells were counted. (n=3) B) PyVmT transfectants were
allowed to migrate to 50, 15, 7.5 and 3.75 nM ligand for 3 hours on fibronectin (10g/ml)
coated membranes. After 3 hours migrated cells in the bottom well of the chemotaxis
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PyVmT-CCR7 tumors were significantly greater than the tumor volumes observed in the 
PyVmT-vector control tumors over the course of the study (Figure 19A and 19B).  On day 48 
post-implantation, tumors in two of the PyVmT-CCR7 mice grew to sizes that were greater than 
20mm in a single dimension, our criterion for euthanization, and were therefore immediately 
removed from the study.  
 
5.3.6  CCR7 Expression Results in Lymph Node Metastasis and Decreased Lung Metastasis  
To determine if CCR7 altered the metastatic behavior of the tumors, we used RT-PCR to 
determine if PyVmT cells were present in the lymph nodes. To this end, we isolated the draining 
lymph node, and used half of the lymph node to isolate mRNA for PCR and used the other half 
for histological preparations.  By PCR we found that 60% of the PyVmT-CCR7 animals 
developed metastases in the draining lymph nodes.  In contrast, 0% of the PyVmT-vector 
controls had metastases within their lymph nodes.  Additionally, we found that while four of the 
PyVmT-CCR7 animals developed metastasis in their lungs, 100% of the PyVmT-vector control 
mice had between one and four metastases in their lungs (Table 2). It is important to note that, on 
blind evaluation of the remaining lymph node tissue, we found that the lymph nodes of the mice 
bearing the PyVmT-CCR7 tumors were dysmorphic and had few if any clear germinal centers, 
when compared to the lymph nodes of the PyVmT-vector control mice, which had clear germinal 
centers and normal morphology (Figure 20).   
 
5.3.7  CCR7 Promotes Increased Growth in Response to CCL19 and CCL21 in 3D Cultures  
To define the mechanism that mediated differences in growth between PyVmT-CCR7 
and PyVmT-vector control animals, we used 2D tissue culture on a flat tissue culture surface.  
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Figure 19. Average tumor volume of CCR7 (+) tumors was significantly greater than
CCR7 (-) tumors on day 48 A) 105 cells were injected into the fifth mammary fat pad of
FVB mice. Palpable tumors were detected as early as day 25 in both groups. Tumors
volume as measured with calipers (length x width x height) was significantly greater in the
PyVmT-CCR7 mice when compared to the PyVmT-vector controls p=0.002. B) At day 48
the average tumor volume of PyVmT-CCR7 tumors (259.9 71.22) was significantly larger













Observed differences in mice injected orthotopically with PyVmT-CCR7 or 
PyVmT-vector control cells
Cell Line Animals with Tumors in 
Lung (average number 
of tumors)
Presence of PyVmT in 
lymph node by PCR
PyVmT-CCR7 4/10 6/10
PyVmT-Vector 10/10 0/10
Table 2. CCR7 promote metastasis of PyVmT cells to the lymph nodes and decreases



















Figure 20. CCR7 disrupts the architecture of lymph nodes. H&E stained histological










We found that when cells were grown on flat surfaces, there was no statistically significant 
difference in the rates of proliferation of CCR7 expressing cells in the presence of CCR7 ligands 
CCL19 and CCL21 (Figure 21A). Indeed, cells grown in the absence of ligand grew marginally 
better than cells grown in the presence of CCL19 or CCL21.  
It is well recognized that growth of tumor cells in three-dimensional (3D) serum free 
mammosphere culture leads to growth of different lineages of epithelial cells [164]. As 
mentioned, CCR7 mediates differentiation of T lymphocytes. Therefore, to determine if CCR7 
promoted growth under conditions that allows differential proliferation of PyVmT we used a 
mammosphere assay. To this end, we allowed PyVmT-CCR7 or PyVmT-vector cells to 
proliferate for seven to ten days in the presence of CCL21 or CCL19 in mammosphere media 
[165]. We observed a significant difference in the size of PyVmT-CCR7 mammospheres when 
compared to PyVmT-vector control mammopsheres (Figure 21B and 21C) and this growth was 
inhibited by blocking β1 integrins in human MCF-7 cells (Figure 22).  These results support the 
increased growth rate of the PyVmT-CCR7 that we observed in our FVB mice in vivo.  From 
these studies we conclude that CCR7 can regulate the size of tumors as well.   
  
5.4  Discussion 
 
In patients with CCR7-expressing breast tumors that had metastasized to the lymph 
nodes, tumor metastases were not found in the lungs, liver or brain, but instead were restricted to 
the surgically removable lymphoid organs [154]. Women with CCR7+  metastases in their 




Figure 21. Expression of CCR7 affects mammosphere size in 3D culture but has no effect
on mammosphere number. A) 105 PyVMT-CCR7 cells were allowed to grow  ligand in 2D
tissue culture for 5 days. Cells were trypsinized and counted, in duplicate. Results are means  
SD. (n=3) B) PyVmT-CCR7 and PyVmT-vector control cells were allowed to grow into
mammospheres in low adhesion plates in the presence of CCL21. C) PyVmT-CCR7 and
PyVmT-vector control cells were allowed to grow in mammosphere media in low adhesion plates










Figure 22. Blocking β1 integrin activation in the presence of CCL19 reduces
mammosphere size. Human MCF-7 cells were plated on low density bindging plate in
mammosphere media and allowed to grow for 9 days. Mammospheres were fixed and size












remained difficult to determine why these women with CCR7 (+) metastases show minimal 
spread beyond lymphoid organs. From our studies, we find that CCR7 expression leads to  
increased growth of tumors while promoting migration to the lymph nodes. It is unclear if CCR7 
prevents cell death or promotes proliferation. Recently, it has been shown that CCR7 prevents 
anoikis of MDA-MB-231, MDA-MB-361 and MDA-MB-453 breast cancer cells and blocks 
apoptosis in hematopoietic cells [166-168].  Since PyVmT-CCR7 mammopsheres grew to 
significantly larger sizes than vector controls, it will be important to use these mammosphere in 
the future in biochemical assays to further our understanding of the mechanisms used by CCR7 
in breast cancer cells to control the extent of tumor growth. 
CCR7 expressing cells travel to lymph nodes and may survive long enough to promote an 
immunological response, which would correlate with improved survival in human breast cancer 
patients [154]. It is tempting to speculate that within lymph nodes these CCR7 expressing tumors 
would co-localize with CCR7-expressing activated dendritic cells, which also express high levels 
of CCL19.  Increased levels of CCL19 have correlated with increased overall survival of human 
breast cancer patients [169]. It likely that controlling migration of breast cancer cells to CCL19 
and CCL21 exposes the tumors to the immune system early during development.  It is unclear 
what events take place within CCR7 (+) breast cancer tumors that control tumor metastases 
numbers, sites and ability to grow.  Due to the inherent nature of CCL19 and CCL21 
chemokines, which mediate recruitment of lymphocytes and organogenesis, it is important to 
consider potential roles for CCR7 in regulation of breast cancer metastasis.   
 It is unclear at what point CCR7 must be expressed to regulate lymph node metastasis or 
tumor growth. As mentioned, in our model, PyVmT cells, which lack endogenous CCR7 
expression, have been selected that metastasize only to the lung [158].  Therefore, we 
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hypothesized that expression of CCR7 would lead to increased migration of breast cancer cells to 
the lymph nodes.  It is unclear what function the lymph nodes play in the development of cancer, 
but we considered several roles.  If the lymph nodes were simply filters, where cells were 
trapped after they exited the tumor, we would have expected to find lymph node metastasis in 
both PyVmT-CCR7 and PyVmT-vector control mice.  In contrast CCR7 could direct metastasis 
to the lymph nodes, the PyVmT-CCR7 tumors would be able to metastasize to the lymph nodes 
earlier than the PyVmT-vector cells, and they would provide the immune system with a possible 
immunogen. In this case they would alert the immune system before the number of PyVmT cells 
reached a critical level where they induced tolerance in the mouse. Studies are underway in our 
laboratories to compare the immune response of the mice transplanted with PyVmT-CCR7 to the 
mice transplanted with PyVmT-vector.   
Our results with our mouse model are supported by recent studies in which in vitro 
studies have demonstrated that CCR7 inhibits post intravasation of mammary cancers [170].  In 
these studies it was also observed that CCR7 failed to affect the growth characteristics of CCR7 
expressing tumors in 2D in vitro cultures.  While they did not examine the metastatic behavior of 
tumors within the mammary fat pad, in support of our studies, these studies observed that when 
Her2/neu (CCR7+) cells were injected directly intravenously, the mice had a reduced capacity to 
develop lung tumors, as well. As mentioned, CCR7 prevents apoptosis but has not been 
implicated in preventing growth of breast cancer.  Therefore, it will be important to determine 
the mechanisms used by CCR7 (+) tumors that prevent growth in peripheral organs, but allow 
growth in lymph nodes.  
We found that stimulation through CCR7 did not affect adhesion of PyVmT-CCR7 to the 
1 integrin, fibronectin in an adhesion assay but that CCR7 promoted migration preferentially to 
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CCL19 but could mediate migration to CCL21 as well.  Since CCR7-expressing tumors grow 
significantly larger when compared to the vector controls, we asked if exposure of PyVmT-
CCR7 to CCL19 or CCL21 could promote proliferation in 3D.  To explore the possibility, we 
examined the growth of PyVmT-CCR7 in mammosphere cultures.  We found that similar to 
what we observed in vivo, PyVmT-CCR7 grew to significantly larger mammospheres when 
compared to vector controls. These results define possible mechanisms used by breast cancer 
tumors that improve overall survival of breast cancer patients with CCR7 expressing breast 
cancer. Studies are currently underway to determine to what extent CCR7 controls differentiation 
of tumors and the signaling events that are activated by CCL19 and CCL21 in breast cancers that 
mediate the changes in the proliferation rate in 3D cultures.  
In conclusion, we have established an MMTV-PyVmT mouse model of breast cancer 
metastasis that allows us to examine the roles of CCR7 in breast cancer progression and 
metastasis.  We have found that similar to what has been observed in cancer patients, CCR7 can 
control tumor metastases in vivo. In this way CCR7 directs PyVmT-CCR7 cells to the lymph 
nodes in vivo, while CCR7 expressing tumors fail to establish lung metastasis. In order to 
metastasize, a tumor must change its adhesive properties and detach from the primary.  To 
determine at what step CCR7 controls tumor metastasis we examined the effect of CCR7 








5.5  Experimental Procedures 
 
5.5.1  Chemicals and Reagents   
Chemicals and reagents were purchased from Sigma unless otherwise specified.  The 
following antibodies were used: M2 (anti-FLAG) and fluorescein-conjugated anti-mouse 
(Jackson Immunoresearch). Murine CCR7 cDNA was a generous gift from James Campbell 
(Harvard Medical School, Boston, MA).  pcDNA3.1 (Invitrogen) or pEGFP-N-1 (Clontech) 
control vectors, fluorescein- conjugated Donkey anti-mouse (Jackson Immuno Labs) and 
fibronectin (Sigma) were purchased.  
 
5.5.2  Cell Lines, Mice and In Vivo Manipulations  
PyVmT cells were generated as described [158]. FVB/N mice were purchased from 
Jackson labs (Bar Harbor, ME).  PyVmT cells were transiently transfected using Lipofectamine 
Plus (Invitrogen) per manufacturer’s instructions, with the following modifications. For adhesion 
assays and in vivo injections, cells were plated at 80% density and transfected 16-24 hours later 
with twice the suggested amount of DNA in serum free DMEM.  Cells were incubated in the 
presence of DNA/Lipofectamine complexes for four hours. The media was adjusted to 10% fetal 
bovine serum, and the cells were allowed to recover overnight.  In the morning, the cells were 
rinsed with PBS and fresh media was added.  Cells were re-transfected each evening on three 
consecutive days.  After the final transfection, cells were trypsinized and plated on Petri dishes 
overnight at 37C in a 5% CO2 humidified atmosphere in complete DMEM 
(10%FBS/90%DMEM/2mM L-glutamine).  Cells were isolated with light trypsin, neutralized 
with cDMEM and injected into the left thoracic mammary fat pad of FVB/N mice (Jackson 
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Labs).  Animals were palpated for tumors starting on day 21, and length, width and height were 
measured with calipers every other day until the tumors reached 20mm in any measurement. At 
that point the animals were euthanized, and the tumors and lungs were collected and processed 
for histology or PCR.  
 
5.5.3  Flow Cytometry   
Transfected PyVmT cells were dissociated from tissue culture with cell dissociation 
solution, rinsed with PBS and labeled with anti-FLAG (M2) antibody (1:1000) for one hour on 
ice in 1%BSA/PBS.  Cells were rinsed 3 x in1% BSA/PBS and labeled with fluorescein- 
conjugated Donkey anti-mouse (1:200) for one hour on ice 1%BSA/PBS.  Cells were rinsed 2 x 
in 1% BSA/PBS, re-
cytometry (FACS-caliber).   
 
5.5.4  Detection of PyVmT Expression in Lungs and Lymph Nodes   
Histological slides were blinded, examined and scored for the presence of metastasis by 
two individuals.  Following physical examination and isolation of the lymph nodes, the DNA 
was extracted using a Qiagen Tissue isolation kit.  DNA was quantified; equal amounts were 
used to amplify PyVmT DNA as described [158]. 
 
5.5.5  Chemotaxis Assays  
Transfected PyVmT cells were dissociated from tissue culture with cell dissociation 
solution, rinsed with PBS and counted. Fifty thousand cells were added in 50µl to the top well of 
a chemotaxis chamber (Neuroprobe) that had been pre-loaded with a 10µg/ml fibronectin-coated 
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5µm membrane and increasing concentration of ligand in each well.  Cells were allowed to 
migrate for three hours. At the end of the assay, the media in the top wells was removed, the 
chamber was disassembled and the cells in the lower wells counted on a hemacytometer.   
 
5.5.6  Mammosphere Cultures   
Six million exponentially growing PyVmT cells were isolated by trypsinization, 
neutralized with complete media, and rinsed twice in PBS and electroporated using a Bio-Rad 
electroporator according to the manufacturer’s protocol (Bio-Rad Bulletin 1349).  Transfected 
cells were isolated by trypsinization and rinsed twice in PBS to remove all traces of serum.  
Single cells were plated on ultra low-attachment six-well plates (Corning; Corning, NY) at a 
density of 30,000 viable cells per well.  Cells were grown in serum-free mammary epithelial 
basal medium (Lonza; Walkersville, MD) supplemented with 20 ng/ml EGF, 5 µg/ml insulin, 1 
µg/ml hydrocortisone (Lonza), 20 ng/ml bFGF, B27 (Invitrogen; Carlsbad, CA), 4 µg/ml heparin 
(MP Biomedicals; Irvine CA), 100 IU/ml penicillin, and 100 µg/ml streptomycin (Mediatech).  
Cells were fed every three days by adding additional media to wells.  Seven days after the initial 
plating, primary mammospheres were measured using a Metamorph.  Significance of difference 
between PyVmT-CCR7 and PyVmT-vector control cells in the presence or absence of ligand 








CHAPTER 6 – DISCUSSION AND FUTURE DIRECTIONS 
 
 
6.1  How the New Conclusions Impact the Field and Future Directions 
 
 The function of CCR7 is to mediate lymph node entry and motility within the lymph 
node, by interacting with the chemokines CCL19 and CCL21.  While both ligands are expressed 
within lymph nodes, CCL21 is also expressed in high endothelial venules, the entry route to 
lymph nodes.  The role of CCL21 in promoting lymph node entry is well established [27, 171]; 
however, as naive T lymphocytes use CCR7 to mediate migration to CCL21, there is still much 
to learn about the molecular mechanisms that are initiated upon ligand binding.  Dendritic cells 
express CCL19, which is important for attracting T lymphocytes into close proximity of 
dendritic cells so that naïve T lymphocytes can become activated [19].  Following dendritic 
cell/T lymphocyte interactions naïve T lymphocytes become activated, exit from the lymph 
nodes and migrate to sites of inflammation.  Paradoxically, without CCL19, T lymphocytes 
become trapped in lymph nodes [34, 36], indicating that further information is needed to fully 
understand the role of CCL19 in lymph node trafficking.   
 In addition to the role of CCR7 in mediating normal homeostasis of circulating T 
lymphocytes, CCR7 and its ligands have also been implicated in progression of autoimmune 
disease.  For example, CCR7 knock out mice display decreased severity of antigen induced 
arthritis (AIA) characterized by decreased knee joint swelling and decreased formation of ectopic 
tertiary lymphoid structures [172].  In support of these findings, CCL21 has been shown to 
promote lymphoid neogenesis in pancreatic islets, which serves to recruit other inflammatory 
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mediators to the pancreas and perpetuates the autoimmune state [35].  In addition, CCL21 
expression is increased on lymphatic endothelial cells in Myasthenia gravis and is thought to 
promote thymic hyperplasia [173].  Similarly, both CCR7 and CCL21 expression are increased 
in graft versus host disease and atopic dermatitis, also serving to recruit other inflammatory 
mediators such as central memory T cells, which maintains the inflammatory response [146].  In 
contrast, studies using CCR7 knock out mice revealed that in the absence of CCR7 mice have 
greater immune infiltrates in the stomach, lung, pancreatic islets and liver, which is a hallmark of 
autoimmunity [174].  Additionally, CCR7 knock out mice spontaneously developed a chronic 
renal autoimmune disorder, similar to systemic lupus erythematosus characterized by glomerular 
IgG deposits, reduction in creatinine clearance and anti-nuclear antibodies [174].  Because the 
presence of CCR7 in some instances seems to yield a protective function against autoimmunity, 
yet in other cases the presence of CCR7 increases the severity of the disease, CCR7 and its 
ligands represent important targets for investigation.  
Similar to T lymphocytes, metastatic breast cancer cells also express CCR7.  It remains 
unclear if CCR7 expression by breast cancer cells promotes metastasis to lymph nodes in vivo 
and what affect this has on disease outcome.  Therefore, using what we learn about CCR7 
mediated migration in T lymphocytes can be used to assist in understanding how breast cancer 
cells also use CCR7 to mediate migration to CCL19 and CCL21 and perhaps how to control 
metastasis.     
The ultimate goal of the work outlined in this dissertation is to contribute to a greater 
understanding of CCR7 mediated migration outlined in the following questions:  1) What are the 
mechanisms by which naïve T lymphocytes are attracted to migrate into lymph nodes?  2)  Does 
CCR7 contribute to egress from the lymph node?  3)  In breast cancer is CCR7 required for 
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lymph node metastasis and does this promote or prevent metastasis to other organs?   4)  Do 
metastatic breast cancer cells hijack CCR7 mechanisms used by T lymphocytes to mediate 
metastasis to lymph nodes?  The results of my dissertation contribute toward the resolution of 
some of these questions. 
 
 
6.1.1  What are the Mechanisms by Which Naïve T Lymphocytes are Attracted to Migrate into 
Lymph Nodes? 
  
Naive T lymphocytes enter into lymph nodes through high endothelial venules, which 
express CCL21.  Additionally, high endothelial venules also express fibronectin [9], which is the 
ligand for the β1 integrin.  Integrins are important adhesion proteins activated by chemokine 
receptors during migration.  As cells migrate they use integrins to adhere to the extracellular 
matrix, which includes proteins such as fibronectin [175].  The cell then propels forward, de-
attaches from the matrix by de-activating the integrins [6].  Then the integrins recycle back into 
the cell in preparation for the next migration cycle [176].  Because high endothelial venules 
express both CCL21 and fibronectin, it is important to understand how and if naïve T 
lymphocytes use CCL21 and fibronectin ultimately to gain entry into lymph nodes. 
While several studies have revealed downstream signaling effectors of CCR7 activation, 
there has been a lack of understanding if these signaling molecules are important for naïve T 
lymphocyte migration.  For example, ERK1/2 has been shown to be transiently phosphorylated 
in response to CCR7 stimulation by CCL21 in primary T lymphocytes and in HEK293 cells [49, 
54], however it is unclear from these studies if phosphorylation of ERK1/2 is necessary for 
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migration.  Similarly, PLCγ1 has been shown to be activated by CCR7 in response to CCL21 in 
highly motile cancer cells [83], yet a possible role in CCR7 mediated T lymphocyte migration 
has not been defined.  The possible role of PLCγ1 in migration is suggested by its ability to bind 
to and activate β1 integrins [62].  Additionally, T lymphocyte activation of CCR7 by CCL21 
leads to adhesion and spreading on VCAM-1, a β1 integrin ligand [4].   
We have found that migration to CCL21 on fibronectin requires ERK1/2, PLCγ1 and Gαi 
activation, however only PLCγ1 is required for β1 integrin activation (Figure 23).  We observed 
that rapid and transient phosphorylation of ERK1/2 is required for migration of naïve T 
lymphocytes to CCL21 on fibronectin, but is not required for initial activation of β1 integrins.  In 
addition, we found that inhibition of PLCγ1 resulted in a loss of naïve T lymphocyte migration to 
CCL21 and β1 integrin activation.  Inhibition of PLCγ1 also resulted in sustained 
phosphorylation of ERK1/2 confirming the importance of transient phosphorylation of ERK1/2 
for migration and suggesting an important role for the recruitment of a phosphatase in response 
to PLCγ1 activation.   In the future it will be important to identify the phosphatase responsible 
for de-phosphorylating ERK1/2.  Two possible phosphatase candidates that could be regulated 
by PLCγ1 include dual specificity phosphatase 2 (PAC-1) and mitogen-activated protein kinase 
phosphatase (MKP-3), which are expressed in T lymphocytes and specifically target ERK1/2 
















Gαi, PLCγ1 and ERK1/2 all Required for 
Migration to CCL21 on Fibronectin
Figure 23. Proposed CCR7/CCL21 signaling in naïve T lymphocytes. We propose that
activation of CCR7 by CCL21 results in Gαi activation , which results in down-stream
phosphorylation of PLCγ1, which in turn results in down-stream transient phosphorylation
of ERK1/2. Inhibition of Gαi, PLCγ1 or ERK1/2 results in a loss of migration to CCL21
on fibronectin. Only inhibition of PLCγ1, but not Gαi or ERK1/2 inhibition, prevents β1
integrin activation. We propose that inhibition of Gαi or ERK1/2 may prevent recycling of







Although CCR7 is well established to mediate migration of T lymphocytes via Gαi 
coupling to the receptor, the downstream signaling events resulting from Gαi activation that are 
required for migration to CCL21 have remained unclear.  We found that both PLCγ1 and 
ERK1/2 phosphorylation was reduced, but not completely lost upon inhibition of Gαi in response 
to stimulation with CCL21.  This suggests that another pathway may also contribute to activation 
of PLCγ1 and ERK1/2.  Other signaling pathways that activate PLCγ1 in T lymphocytes 
includes stimulation of growth factor receptors and T cell receptors [178].   Because inhibition of 
Gαi reduced migration to CCL21 without preventing the initial activation of β1 integrins, one of 
these other signaling pathways may have initiated β1 integrin activation while Gαi-induced 
PLCγ1 activation.   Other Gαi-dependent signaling pathways may be important for de-attaching 
or recycling of β1 integrins.   
Another possible mechanism for Gαi-independent activation of β1 integrins is activation 
of the Janus Kinase-2 (JAK-2) non-receptor tyrosine kinase [179], which could also explain the 
reduction, but not complete loss of PLCγ1 and ERK1/2 phosphorylation in response to pertussis 
toxin.  Several studies report that ligand binding to GPCRs initiate the traditional G-protein 
pathway and the JAK/STAT signaling pathway [180-182].  Interestingly, inhibition of JAK-2 
kinase resulted in decreased β1 integrin activation independent of Gαi activation in response to 
CCL21 stimulation of CCR7 [179], providing a possible explanation for our results.  In the 
future it will be important to carry out studies to inhibit both Gαi and JAK-2 in order to 
understand if these pathways work together to contribute to β1 integrin mediated migration to 
CCL21 on fibronectin.  Additionally, it will be important to further understand how inhibition of 
JAK-2 affects PLCγ1 and ERK1/2 signaling. 
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Integrins are unique receptors in that they undergo bi-directional signaling.  Integrins can 
be signaled to from another receptor, such as CCR7 a process termed “inside out” signaling.  
Integrins can also signal through “outside in” signaling via interaction with a ligand.  Our work 
demonstrates that CCL21 signals to activate β integrins through “inside out” signaling.  However 
β1 integrins also signal upon contact with fibronectin which also contributes to CCR7 motility 
through “outside in” signaling.  It will be important to further understand how these two 
pathways converge to mediate migration by co-incubating both CCL21 and fibronectin and 
observe changes in signaling compared to fibronectin or CCL21 alone.  β1 integrins also 
phosphorylate PLCγ1 in order to mediate motility [84], so one could speculate that in vivo when 
a T lymphocyte encounters CCL21 and fibronectin both signals combined further amplify 
activation of PLCγ1 in order to promote continuous migration.  This is significant, because as 
naïve T lymphocytes migrate through the high endothelial venules to enter into lymph nodes, the 
lymphocytes will encounter both CCL21 and fibronectin signals at the same time and in the 
future it may be important to not only inhibit CCL21, but also inhibit β1 binding to fibronectin to 
completely inhibit migration.   
 Taken together, our working model is that PLCγ1 is required for migration to CCL21 
and activation of β1 integrins, while Gαi and ERK1/2 are required for migration.  PLCγ1 
promotes migration by terminating phosphorylation of ERK1/2 via activation of an unknown 
phosphatase.  Gαi contributes to migration by activating PLCγ1.  At this point it remains unclear 
as to the mechanism of how ERK1/2 is phosphorylated since Gαi inhibition only partially 
decreases ERK1/2 activation.  Further, it is uncertain if ERK1/2 is continually cycling between 
phosphorylated and de-phosphorylated states or if once de-phosphorylated, ERK1/2 remains de-
phosphorylated for the duration of the migration event.  It is also unclear if PLCγ1 directly 
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activates the phosphatase that de-phosphorylates ERK1/2 or if there is a signaling intermediate.  
It will be important to identify other signaling molecules activated by CCR7 in response to 
CCL21 in order to better understand how PLCγ and ERK1/2 contribute to migration.   
This work contributes to the greater understanding of the mechanisms required for T 
lymphocyte migration and in the future it will be important to continue to define mechanisms 
that are important for migration to CCL21.  As CCL21 is important for T lymphocyte entry into 
lymph nodes, it is important to understand if blocking this event could alter the course of an 
immune response.  An antagonist of CCL21 (mSLC4) was found to reduce the severity of graft 
versus host disease in mice, which was contributed to a reduction in CD4+ cells, which in turn 
reduced activated B lymphocytes [37].  Perhaps one could develop specific targets against the T 
cell receptor that recognizes a specific self antigen, coupled with a CCL21 antagonist.  This 
would allow one to specifically target those T lymphocytes engaged in attacking the body and 
prevent them from entering into lymph nodes to become activated without affecting the entire 
immune system.  Therefore, CCL21 represents an important target for manipulation of the 
immune response.  Certainly, more work is needed to continue to increase our knowledge of 
CCL21 mediated mechanisms that will hopefully serve to identify specific inhibitors that can 
possibly be used to treat disease in the future.      
 
 
 6.1.2  Does CCR7 Contribute to Egress From the Lymph Node?   
 
 As mentioned during normal homeostasis naïve T lymphocytes are in continuous 
migration throughout the lymph nodes.  Although it is very important that these cells are able to 
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migrate into lymph nodes, it is imperative they also be able to migrate out in order to continue to 
scan for antigen and carry out effector functions in the periphery.  During an immune response 
naïve T lymphocytes enter into lymph nodes and immediately begin scanning dendritic cells that 
present antigen.  The close proximity of dendritic cells to the high endothelial venules, the route 
by naïve T lymphocytes enter into lymph nodes,  as well as expression of CCL19 by dendritic 
cells facilitate these interactions [19, 183].  Once T lymphocytes recognize antigen they form 
stable interactions with dendritic cells that can last upwards of 36-48 hours [22].  During this 
prolonged interaction the T lymphocyte becomes activated, begins to proliferate and eventually 
detaches from the dendritic cell [23].  Lastly, the activated T lymphocytes exit the lymph nodes 
and return to the circulation to carry out their effector functions in the periphery.   
The S1P1 receptor has been well defined for its role in promoting lymph node egress [65, 
123].  When naïve T lymphocytes first enter into the lymph nodes, S1P1 levels are low so as to 
not cause exit prematurely before having the opportunity to locate antigen [184].  However, after 
some point when the cell receives a signal to exit, S1P1 is up-regulated.  The molecular 
mechanisms that mediate up-regulation of S1P1 in order to initiate lymph node egress are still not 
understood.  Two separate studies carried out with a CCL19-deficient mouse and a CCL19 
antagonist (8-83) demonstrated that without CCL19 function T lymphocytes were retained in 
lymph nodes during normal homeostasis and during immune responses [34, 36].  Furthermore, in 
CCR7-deficient mice, S1P1 levels were also found to be decreased [69], suggesting that CCR7 
expression may be important for S1P1 expression.   
Together, these studies suggest a role for CCR7/CCL19 in mediating lymph node egress.  
We first made the observation that T lymphocytes treated with CCL19, but not CCL21 migrate 
to S1P, at 48 hours, suggesting that CCL19-treated cells had increased expression of S1P1.  
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Importantly, CCL19-treated cells did not migrate to S1P until 48 hours after treatment.  The 
significance of this timing correlates with T lymphocytes losing the ability to migrate to S1P in 
vivo 24 hours after entering into lymph nodes [64], then regaining the ability to migrate to S1P 
by 72 hours [65].  To investigate the mechanism of up-regulation of S1P1 we assayed for 
changes in protein expression of ERK5 and KLF-2 following treatment with CCL19.  We found 
that activation of CCR7 by CCL19 over the course of 24-72 hours increased phosphorylation of 
ERK5 and up-regulated total levels of both ERK5 and KLF2, suggesting a mechanism for the 
increase in S1P1 levels and increased migration observed to S1P at 48 hours (Figure 24).  Our 
proposed ERK5 pathway was further supported when we used siRNA to knock down ERK5 and 
found that CD4+/CD8+ T lymphocytes failed to exit lymph nodes and displayed decreased 
migration to S1P 48 hours following CCL19 treatment.   
Taken together, our results suggest that CCR7activation by CCL19 is important for 
turning on the machinery that regulates lymph node exit via S1P1.  In the future, it will be 
important to determine the impact of inhibiting the CCR7/CCL19/ERK5 pathway on the immune 
response or other cellular functions.  This is of great interest since FTY720, an inhibitor of S1P1, 
is currently being used in phase III clinical trials to treat multiple sclerosis [185, 186].  It is 
interesting to speculate which ligand, CCL21 or CCL19 or both, would be most effective at 
inhibiting the immune response.  As CCL21 is important for entering the lymph nodes one could 
argue that preventing these cells from ever entering the lymph nodes would be important for 
diminishing any possible immune response.  However it seems that during immune responses T 
lymphocytes can find alternative ways to enter into lymph nodes such as through the afferent 
lymphatics and can bypass CCR7 ligands altogether [187], which might still result in enough T 















Figure 24. Proposed CCL19/CCR7 signaling required for increased expression of S1P1.
We propose that activation of CCR7 by CCL19 results in phosphorylation of ERK5, which
increases transcription of KLF-2, which in turn promotes increased transcription of S1P1. We
found that treatment of Hut78 human T lymphocytes and primary murine T lymphocytes with
CCL19 over the course of 48 hours increased phosphorylation of ERK5 and increased overall
total protein levels of ERK5. We observed also that KLF-2 protein levels were increased
over this same time period. After 48 hours of CCL19 treatment, cells were able to migrate to
S1P, suggesting increased S1P1 receptor on the surface of these cells. Increased S1P1 mRNA
was confirmed by RT-PCR. Knock down of ERK5 resulted in decreased migration of T





Therefore, one might argue that inhibiting both ligands would provide the best alternative 
to not only prevent entry but for those lymphocytes that do enter, also block exit to ensure that 
you could control the entire T lymphocyte response.  One important consequence of inhibiting 
CCL21 and CCL19 together is that in plt mice, which lack both ligands CCL19 and CCL21, 
immune responses are delayed initially but ultimately enhanced over a period of 20 days [187], 
which would be detrimental in autoimmune disease.  As the plt mouse is a result of a 
spontaneous mutant that deletes both CCL19 and CCL21, it is unclear if both ligands contribute 
to the delayed but enhanced response.  Therefore, it will be important in the future to use the 
antagonists CCL19 (8-83) and CCL21 (mSLC4) together and individually to understand if the 
impact of blocking both ligands or simply one ligand CCL19 or CCL21 results in a similar 
enhanced response.  In contrast, a delayed but enhanced immune response would be very 
beneficial with respect to vaccinations and even possibly to boost immunity during bacterial and 
viral infections.  Taken together, there are still many questions that need to be answered, but our 
findings contribute to the current knowledge of how T lymphocytes emigrate into the periphery 
and define additional potential therapeutic targets that could possibly be used in either in 
combination with FTY720 or alone to treat autoimmune disease.   
 
6.1.3  In Breast Cancer is CCR7 Required for Lymph Node Metastasis and Does This Promote or 
Prevent Metastasis to Other Organs? 
 
 Recent studies have found strong correlations between patients who develop CCR7 
expressing breast cancers and metastasis to lymph nodes, which highly express CCR7 ligands. 
[73, 75].  However, a contrasting study determined that CCR7 expression did not correlate with 
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lymph node metastasis in breast cancer [76].  At present, it is unclear if and by what mechanisms 
CCR7 controls lymph node metastasis in breast cancer.  We have demonstrated in a mouse 
model that CCR7(+) breast cancer cells preferentially metastasize to lymph nodes, while CCR7(-
) cells metastasized to the lung and were not found in the lymph node.  Several studies have 
reported that CCR7(+) tumors result in overall decreased patient survival however, it remains 
uncertain as to why patient survival is decreased [73].  In contrast, other studies suggest that 
CCR7(+) tumors have no effect on overall survival [154].  In most breast cancer cases, axillary 
lymph nodes are removed without any understanding if removal affects overall patient survival 
[74].  Unexpectedly, we found that while CCR7(+) mice that had preferential metastases to the 
lymph nodes, that lung metastases were reduced.   
As lymph nodes are important sites for activation of lymphocytes, it seems counter 
intuitive that cancer cells would dare up-regulate receptors that would allow migration into these 
areas, as these are places of highly activated lymphocyte, that could potentially kill the cancer 
cells right then and there.  Therefore, it is possible that in our model CCR7(+) cells were directed 
into the lymph nodes where they come into direct contact with lymphocytes that resulted in the 
mounting of a stronger immune response against the metastatic cancer cells, thus preventing 
further metastases to distant organs.   
Alternatively, one could argue that cancer cells migrating into lymph nodes could provide 
an advantage for the cancer cells, such as inducing immunologic tolerance.  Tolerance is 
characterized by the lack of an immune response directed toward specific antigens, such as 
tumor antigen.  The induction of tolerance may provide an explanation as to why in some cases 
CCR7(+) tumors correlate with a worse patient outcome.  It is difficult at this stage to fully 
understand the dynamics of what is occurring in lymph nodes when breast cancer metastases 
97 
 
migrate to these locations.  It will be important to analyze the immune response in CCR7(+) 
breast cancers  to understand if the immune response is enhanced or down-regulated as compared 
to CCR7(-) breast cancers.  For example, one could begin by using the CCR7
-/-
 mouse model and 
assaying for numbers of T regulatory cells, which are important for down-regulating the immune 
response.  Additionally, one could isolate CD8+ cytotoxic T cells from mice who have 
developed tumors and perform cytotoxic killing assays with PyVmT cells isolated from CCR7+ 
and CCR7- tumors and metastasis.  Furthermore, because we found that lymph nodes metastases 
resulted in decreased metastases to the lung, more work is needed to fully understand the impact 
of removal of lymph nodes during disease progression, as we are not yet certain if this affects the 
immune response and/or metastatic outcome CCR7(+) breast cancer patients.  Removal of lymph 
nodes could result in increased metastases to more distant locations simply because cancer cells 
that would normally migrate into lymph nodes are possibly directly exposed to antigen 
presenting cells that could take up antigen from dead or dying cancer cells and effector cytotoxic 
cells that could directly kill the cancer cell.  Ultimately much more work is needed to fully 
understand the role of CCR7 and the role of lymph nodes in breast cancer metastasis.     
 
6.1.4  Do Metastatic Breast Cancer Cells Hijack CCR7 Mechanisms Used by T Lymphocytes to 
Mediate Metastasis to Lymph Nodes? 
  
 As mentioned in Chapter 1, lymphocyte migration is a complex process in which the cell 
activates adhesive contacts to adhere to extracellular molecules [1].  The cell then spreads in 
order to be propelled over the extracellular matrix and then de-activates its adhesive contacts to 
release from the extracellular matrix, to repeat the cycle again [7].  In naïve T lymphocytes, both 
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CCR7 and β1 integrins are important for mediating migration into lymph nodes.  Naïve T 
Lymphocytes enter into lymph nodes via high endothelial venules, which express CCL21 as well 
as fibronectin, a β1 integrin ligand [9].  Importantly, CCR7 has been shown to mediate migration 
of T lymphocytes to CCL21 on a β1 integrin ligand.  Specifically, T lymphocyte activation of 
CCR7 by CCL21 leads to adhesion and spreading on VCAM-1, a β1 integrin ligand, resulting in 
migration to CCL21 [4].  In response to CCR7 activation by CCL21, T lymphocytes activate 
several important mediators that regulate migration and β1 integrin activation.  For example, we 
observed that both ERK1/2 and PLCγ1 are necessary for migration to CCL21 on the β1 integrin 
ligand fibronectin.  In addition, JAK-2 is required for β1 integrin activation in response to 
CCL21 activation and is required for migration to both CCL19 and CCL21 [179].     
Similar to T lymphocytes, metastatic breast cancers also express CCR7 and β1 integrins.  
In contrast to the primary tumor, metastatic breast cancer cells display increased expression of β1 
integrins on their cells surface [85].  Blocking β1 integrins reverts the malignant phenotype of 
these breast cancer cells to a normal epithelial phenotype, characterized by well organized actin, 
organized adherens junctions, deposition of a basement membrane and growth arrest [85].  
Therefore, it is important to understand how β1 integrins are regulated in breast cancer cells and 
use our knowledge of how T lymphocytes signal to and regulate β1 integrins so that we can 
begin to understand this process in breast cancer.     
While breast cancer cells migrate to CCL19 and CCL21, it is not clear if breast cancer 
cells can signal through CCR7 to regulate β1 integrin mediated adhesion or migration similar to 
T lymphocytes.  Migration is a multi-step process in which cells must adhere, spread and de-
adhere with each step relying greatly on integrin interactions with extracellular matrix molecules.  
We found that activation of CCR7 was not important for β1 mediated cell adhesion or initial 
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activation of the β1 integrin in PyVmT murine breast cancer cells.  However, CCR7 activation 
by CCL19 did promote β1 integrin-specific spreading.  These results suggested that CCR7 
signals to β1 integrins to promote migration.  In support of this model, we found that CCR7-
induced breast cancer cell migration to both CCL19 and CCL21 on fibronectin.  In vivo T 
lymphocytes travel into lymph nodes via high endothelial venules which express CCL21 and 
fibronectin.  Therefore, these results support our mouse model results from the previous section 
in which CCR7 promoted lymph nodes metastasis.  Furthermore, these results suggest that CCR7 
can promote migration, similar to that seen with T lymphocytes, under similar conditions 
presented in high endothelial venules.  In the future it will be important to begin to understand 
the molecular mechanisms that contribute to CCR7-mediated migration to both CCL19 and 
CCL21.  For example, it will be important to understand the role of PLCγ1, as it is not only 
important during CCR7/CCL21 activation and mediated migration, but is also activated in 
response to β1 integrin binding of ligands.  Additionally, ERK1/2 is also activated in response to 
CCL19 and CCL21 stimulation of CCR7 in T lymphocytes and may play an important role in 
breast cancer migration as well.      
One hallmark of cancer is the ability to undergo uncontrolled cell proliferation.  In 
metastatic breast cancer cells β1 integrins promote proliferation [188].  Since we observed CCR7 
mediated migration on β1 integrins, suggesting the possibility that CCR7 signals to β1 integrins, 
we questioned if activation of CCR7 by CCL19 or CCL21 could promote growth of breast 
cancer cells, possibly via a β1 integrin mediated mechanism.  We found that both CCL19 and 
CCL21 promoted growth of breast cancer cells, while β1 integrin inhibition decreased growth in 
the presence of CCL19.  These results were further supported in vivo as CCR7(+) breast cancer 
tumors displayed an increase in tumor volume compared to CCR7(-) tumors.  It is important to 
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take into consideration that increased growth could be a result of increased proliferation, 
increased survival or decreased death signals.  Therefore, it will be important to assay for 
changes in anti-apoptotic mediators such as Bcl-2, apoptotic mediators such as caspase-3 and 
proliferation markers such as Ki-67 in order to further understand how activation of CCR7 can 
affect growth in breast cancer cells.   
 Taken together, our data suggest that CCR7 mediates spreading, migration and growth of 
metastatic breast cancer cells.  In the future it will be important to continue to learn what CCR7-
mediated mechanisms are important for breast cancer migration and metastasis as this knowledge 
could be used to develop drug targets.  This will help us to understand to a greater extent if 
CCR7 behavior in breast cancer cells will resemble that observed in T lymphocytes.   This is 
significant, because if CCR7 becomes a therapeutic target for metastatic breast cancer and CCR7 
activates similar signaling pathways in T lymphocytes, the immune system will also be affected 
with any drugs developed to target CCR7 expressing breast cancer cells.   
 
 
6.2  Concluding Remarks 
 
Taken together, the work carried out in this dissertation contributes to a deeper 
understanding of the molecular mechanisms that are carried out in response to activation of 
CCR7 by its ligands CCL19 and CCL21.  Furthermore, we have identified a novel and important 
function of the CCR7 receptor in naïve T lymphocytes, to regulate lymph node egress.  We have 
also learned that CCR7 promotes breast cancer metastasis to lymph nodes, while reducing 
metastasis to other vital organs.  If metastatic breast cancers use similar CCR7 mediated 
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mechanisms as T lymphocytes to mediate egress from lymph nodes, the findings outlined in this 
dissertation could eventually lead to additional molecular targets for cancer therapies.  Currently, 
a S1P specific antibody (ASONEP) has been found in vivo to reduce metastasis and is currently 
in phase 1 clinical trials [189].  Overall the information presented in this dissertation provides 
new insights, yet also raises important questions that hopefully someday will lead to a better 
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